Production method for genome-edited cells

The method of using guide RNAs with added nucleotides and spacer mismatches in the CRISPR/Cas system enables selective editing of one allele, addressing the issue of unintended mutations in genome editing, thereby improving precision and safety.

JP2024160413APending Publication Date: 2024-11-13KYUSHU UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024147493
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-12-12
Filing Date
2024-08-29
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

Existing genome editing technologies using CRISPR/Cas systems often induce unexpected genetic mutations, particularly through non-homologous end-joining (NHEJ), which can affect both alleles and introduce indels, posing risks to normal genes during editing, especially when attempting to knock out disease genes or introduce normal genes.

Method used

A method involving guide RNAs with added nucleotide residues at the 5' end and spacer sequence mismatches to target sequences, combined with Cas proteins, is used to selectively edit only one allele, minimizing indels and mutations by optimizing the genome editing process.

Benefits of technology

This approach allows for precise editing of one allele while reducing unintended mutations, enhancing the safety and accuracy of genome editing by suppressing off-target effects and maintaining on-target activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024160413000008
    Figure 2024160413000008
  • Figure 2024160413000009
    Figure 2024160413000009
  • Figure 2024160413000010
    Figure 2024160413000010
Patent Text Reader

Abstract

To provide a production method for genome-edited cells.SOLUTION: A production method for a cell in which only one allele is genome-edited includes: a step of introducing, into a cell, (A) at least one selected from the group consisting of (a1) a guide RNA in which one or more nucleotide residues are added to a 5'-end of a spacer sequence, (a2) a guide RNA containing a spacer sequence having single-base or multiple-base mismatches with respect to a target sequence, and (a3) an expression vector that can cause the guide RNA of (a1) or (a2) to be expressed, and (B) at least one selected from the group consisting of a Cas protein and an expression vector that can cause the Cas protein to be expressed.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of genome editing. In particular, the present invention relates to a method for producing a cell in which only one allele is genome-edited, a guide RNA, an expression vector, and a kit that can be used in the production method, and a method for predicting genome editing patterns. Furthermore, the present invention relates to a method for analyzing genome editing patterns and cells that can be used in the analysis method. This application claims priority based on Japanese Patent Application No. 2018-232946, filed on December 12, 2018, the contents of which are incorporated herein by reference. [Background technology]

[0002] Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), together with CRISPR-associated (Cas) genes, are known to constitute an adaptive immune system that provides acquired resistance to invading foreign nucleic acids in bacteria and archaea. CRISPRs are often derived from phages or plasmid DNA and consist of short conserved repeated sequences of 24-48 bp interleaved with unique variable DNA sequences of similar size called spacers. In addition, a group of genes encoding the Cas protein family is present in the vicinity of the repeats and spacer sequences.

[0003] In the CRISPR / Cas system, foreign DNA is cut into fragments of about 30 bp by the Cas protein family and inserted into CRISPR. Cas1 and Cas2 proteins, which are part of the Cas protein family, recognize a base sequence called proto-spacer adjacent motif (PAM) in foreign DNA, cut out the upstream of it, and insert it into the CRISPR sequence of the host, which becomes the bacterial immune memory. The RNA (called pre-crRNA) generated by transcription of the CRISPR sequence containing the immune memory pairs with a partially complementary RNA (trans-activating crRNA: tracrRNA) and is incorporated into the Cas9 protein, which is a member of the Cas protein family. The pre-crRNA and tracrRNA incorporated into Cas9 are cut by RNAase III to become small RNA fragments (CRISPR-RNAs: crRNAs) containing the foreign sequence (guide sequence), and the Cas9-crRNA-tracrRNA complex is formed. The Cas9-crRNA-tracrRNA complex binds to foreign invasive DNA that is complementary to the crRNA, and the Cas9 protein, a DNA-cutting enzyme (nuclease), cuts the foreign invasive DNA, thereby suppressing and eliminating the function of the exogenous DNA.

[0004] The Cas9 protein recognizes the PAM sequence in foreign invasive DNA and cleaves the double-stranded DNA upstream of the PAM sequence to create blunt ends. The length and base sequence of the PAM sequence vary depending on the bacterial species, and Streptococcus pyogenes (S. pyogenes) recognizes the three bases "NGG". Streptococcus thermophilus (S. thermophilus) has two Cas9s, each of which recognizes 5-6 bases of "NGGNG" or "NNAGAA" as the PAM sequence. (N represents any base.) The number of bp upstream of the PAM sequence that is cleaved also varies depending on the bacterial species, but most Cas9 orthologs, including S. pyogenes, cleave 3 bases upstream of the PAM sequence.

[0005] In recent years, there has been active development of technology that applies the bacterial CRISPR / Cas system to genome editing. crRNA and tracrRNA are fused together to express and utilize tracrRNA-crRNA chimeras (sgRNA). This attracts RNA-guided nuclease (RGN) and cuts genomic DNA at the desired site. There are three types of CRISPR / Cas systems: type I, type II, and type III. The type II CRISPR / Cas system is used exclusively for genome editing, and the Cas9 protein is used as the RGN in type II. The Cas9 protein derived from S. pyogenes recognizes the triplet NGG as a PAM sequence, so it can cut upstream of any sequence with two guanines in a row. The method using the CRISPR / Cas system requires only the synthesis of a short sgRNA with a sequence homologous to the target DNA sequence, and genome editing can be performed using a single protein, the Cas9 protein. Therefore, unlike the conventional zinc finger nucleases (ZFNs) and transactivator-like effectors (TALENs), it is not necessary to synthesize large proteins for each DNA sequence, and genome editing can be performed simply and quickly. For example, Patent Document 1 discloses a genome editing technique that utilizes the CRISPR / Cas system derived from S. pyogenes. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] International Publication No. 2014 / 093661 Summary of the Invention [Problem to be solved by the invention]

[0007] It is known that DNA double-stranded breaks caused by genome editing are repaired by homologous directed repair (HDR) or non-homologous end-joining repair (NHEJ). During NHEJ, insertions and / or deletions (insertion / deletion: indel) are frequently induced during repair, which may result in unexpected gene mutations. For example, if a patient has a heterozygous disease gene and a normal gene, attempting to knock out the disease gene by genome editing may induce mutations in the normal gene at high frequency. In addition, even if a patient attempts to knock in the normal gene by HDR, the probability of knock-in occurring in both alleles is extremely low. Therefore, in the allele where knock-in is not induced, there is a risk that indels will be introduced by NHEJ. Therefore, if genome editing creates double-stranded breaks in both alleles, there is a risk that unexpected mutations will be induced in one of the alleles.

[0008] The present invention has been made in view of the above circumstances, and aims to provide a method for producing cells in which only one allele has been genome-edited, as well as a guide RNA, an expression vector, and a kit that can be used in the method. Further, the present invention aims to provide a method for predicting genome editing patterns, a method for analyzing genome editing patterns, and cells that can be used in the analysis method. [Means for solving the problem]

[0009] The present invention includes the following aspects. [1] A method for producing a cell in which only one allele has been genome-edited, comprising the steps of: (A) introducing into a cell at least one selected from the group consisting of (a1) a guide RNA having one or more nucleotide residues added to the 5' end of the spacer sequence, (a2) a guide RNA comprising a spacer sequence having a mismatch of one or more bases with respect to a target sequence, and (a3) ​​an expression vector for the guide RNA of (a1) or (a2); and (B) at least one selected from the group consisting of a Cas protein and an expression vector thereof. [2] The method for producing a cell in which only one allele has been genome-edited, as described in [1], wherein (A) is a guide RNA or an expression vector encoding the same, in which one or more nucleotide residues are added to the 5' end of the spacer sequence, and the spacer sequence has a mismatch of one or more bases with respect to the target sequence. [3] A method for producing a cell in which only one allele has been genome-edited, as described in [1] or [2], wherein all of the nucleotide residues added to the 5' end of the spacer sequence are identical nucleotide residues. [4] The method for producing a cell in which only one allele has been genome-edited, described in [3], wherein the nucleotide residue added to the 5' end of the spacer sequence is a cytosine residue or a guanine residue. [5] A method for producing a cell in which only one allele has been genome-edited, according to any one of [1] to [4], further comprising the step of (C) introducing a donor vector into the cell. [6] The method for producing a cell in which only one allele has been genome-edited according to any one of [1] to [5], wherein the Cas protein is a Cas9 protein. [7] A guide RNA with one or more nucleotide residues added to the 5' end of the spacer sequence. [8] The guide RNA according to [7], wherein the spacer sequence has one or more mismatches with the target sequence. [9] An expression vector for a guide RNA according to [7] or [8].

[10] Furthermore, the expression vector described in [9] is capable of expressing a Cas protein.

[11] The expression vector according to

[10] , wherein the Cas protein is a Cas9 protein.

[12] (A) A kit for producing a cell in which only one allele has been genome-edited, comprising at least one member selected from the group consisting of: (a1) a guide RNA having one or more nucleotide residues added to the 5' end of a spacer sequence; (a2) a guide RNA comprising a spacer sequence having a mismatch of one or more bases with respect to a target sequence; and (a3) ​​an expression vector for the guide RNA of (a1) or (a2).

[13] (B) A manufacturing kit described in

[12] , further comprising at least one selected from the group consisting of Cas proteins and their expression vectors.

[14] A method for predicting a genome editing pattern, comprising: (i) a step of introducing a guide RNA or an expression vector thereof, and a Cas protein or an expression vector thereof into a cell to perform genome editing; (ii) a step of extracting DNA from the cell where the genome editing has been performed; (iii) a step of amplifying a DNA fragment including a target region from the DNA; (iv) a step of performing sequence analysis of the amplified DNA fragment to determine an indel induction rate (P) in the target region; and (v) a step of determining an indel induction rate for only one allele (mono) and an indel induction rate for both alleles (bi) using the following formula (m) or (m1) and (b) or (b1): mono = 2 × P × (1-P) (m) bi=P 2 (b) mono=-1.303P 2 +1.2761P+0.0274 ···(m1) bi=0.6515P 2 +0.3619P-0.0137 ···(b1)

[15] A cell comprising, in one allele, a chimeric gene in which a localization protein coding sequence, a cleavage site, and a first fluorescent protein coding sequence are linked in frame in this order, and, in the other allele, a chimeric gene in which the localization protein coding sequence, the cleavage site, and a second fluorescent protein coding sequence are linked in frame in this order.

[16] A method for analyzing a genome editing pattern, comprising: (I) a step of introducing a guide RNA or an expression vector thereof targeting the cleavage site, and a Cas protein or an expression vector thereof into the cell described in

[15] to perform genome editing; (II) a step of analyzing the fluorescence pattern of the cell after the step (I); and (III) a step of determining the genome editing pattern based on the fluorescence pattern analyzed in the step (II). Effect of the Invention

[0010] According to the present invention, there are provided a method for producing a cell in which only one allele has been genome-edited, a guide RNA, an expression vector, and a kit that can be used in the method. Further, there are provided a method for predicting genome editing patterns, a method for analyzing genome editing patterns, and cells that can be used in the analysis method. [Brief description of the drawings]

[0011] [Figure 1A] BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is a diagram illustrating an outline of the AIMS constructed in the Examples. Fig. 1A is a diagram illustrating the gene constitution of the AIMS cell prepared in the Examples. [Figure 1B] FIG. 1B is a diagram illustrating the method for evaluating indels by AIMS. [Figure 1C] FIG. 1C shows the P2A peptide coding sequence used in the preparation of AIMS cells in the Examples, and the aP2A sequence in which silent mutations have been introduced into said sequence. [Figure 2A] FIG. 1 shows the structure of the plasmid used for genome editing in the examples. [Figure 2B] FIG. 1 shows the procedure after transfection of the plasmid used for genome editing in the examples. [Figure 3A] 3A to 3B show the results of investigating whether the introduction rate of bilateral indels and unilateral indels changes by introducing a single base mismatch into the spacer sequence of sgRNA with respect to the target sequence. Figure 3A shows an example of the spacer sequence used in the examples. [Figure 3B]Figure 3B shows the results of indel pattern analysis using Tbx3-P2A-AIMS as AIMS cells. [Figure 3C] FIG. 3C shows the results of indel pattern analysis using Tbx3-P2A-AIMS as AIMS cells. [Figure 3D] Figure 3D shows the results of indel pattern analysis using Cdh1-aP2A-AIMS as AIMS cells. [Figure 4A] 4A to 4F show the results of investigating whether the introduction rate of bilateral indels and unilateral indels changes by adding nucleotide residues to the 5' end of the spacer sequence of sgRNA. Figure 4A shows an example of sgRNA used in the examples. [Figure 4B] Figure 4B shows the results of indel pattern analysis using Cdh1-P2A-AIMS as AIMS cells. [Figure 4C] FIG. 4C shows the results of indel pattern analysis using Cdh1-P2A-AIMS as AIMS cells. [Figure 4D] Figure 4D shows the results of an investigation into whether the introduction rates of bilateral indels and unilateral indels change by changing the amount of sgRNA expression plasmid to be transfected. [Figure 4E] Figure 4E shows the results of an investigation into whether the introduction rate of bilateral indels and unilateral indels changes by changing the amount of sgRNA expression plasmid to be transfected. The Cas9 and puromycin resistance gene expression plasmid and the sgRNA expression plasmid were separated into separate plasmids, and only the amount of the sgRNA expression plasmid was changed. [Figure 4F] Figure 4F shows the results of genome editing targeting the Rosa26 and albumin genes (Alb). An sgRNA with a cytosine (C) added to the 5' end of the spacer sequence was used. [Figure 5A]5A to 5C show the results of evaluating the introduction rate of indel-free homologous recombination using AIMS cells. FIG. 5A is a diagram for explaining an outline of the method used in Example 5. [Figure 5B] FIG. 5B shows the results of homologous recombination using sgRAN containing a spacer sequence with a one-base mismatch. [Figure 5C] FIG. 5C shows the results of homologous recombination using sgRAN in which cytosine was added to the 5′ end of the spacer sequence. [Figure 6A] 6A to 6C show the results of investigating whether the introduction rate of bilateral indels and unilateral indels changes by combining the introduction of a single base mismatch with the addition of a nucleotide residue to the 5' end. Figure 6A shows the results of using an sgRNA having a single base mismatch with respect to the target sequence. [Figure 6B] Figure 6B shows the results of using an sgRNA that has a one-base mismatch with the target sequence and contains a spacer sequence with 10 cytosines added to the 5' end. [Figure 6C] Figure 6C shows the results of using an sgRNA that has a one-base mismatch with the target sequence and contains a spacer sequence with 25 cytosines added to the 5' end. [Figure 7] FIG. 1 shows the correlation between the frequency of uniallelic indels calculated by formula (m) described in Example 7 and the frequency of uniallelic indels actually detected in FIGS. 3B to 3D, 4B, and 6A to 6C. [Figure 8A] 8A to 8B show the results of comparing the predicted values ​​of Pre-Demo-Prediction with the actual measured values. Fig. 8A shows the operation protocol of Pre-Demo-Prediction. [Figure 8B] FIG. 8B shows the predicted values ​​(left graph) and the actual measured values ​​(right graph) of Pre-Demo-Prediction. [Figure 9A]The results of an investigation into whether off-target effects can be suppressed by adding a nucleotide residue to the 5' end of the spacer sequence are shown in Fig. 9. Figure 9A shows the results of calculating the indel induction rate (P) using the formula (1) described in Example 7 based on the data in Figs. 6A to 6C. [Figure 9B] 9B shows the results of verifying the effect of adding cytosine to the 5' end of the spacer sequence on suppressing off-target action. An sgRNA expression vector in which 0, 10, or 25 cytosines were added to the 5' end of the spacer sequence for the target sequence in the EMX1 gene (GAGTCCGAGCAGAAGAAGAA: 5th to 24th positions of SEQ ID NO: 83) was introduced into HEK293T, and indels were verified in the on-target region and the off-target region, the MFAP1 gene region (GAGTCtaAGCAGAAGAAGAA: SEQ ID NO: 91; the parts different from the target sequence in the EMX1 gene are shown in lower case). [Figure 9C] Figure 9B shows the results of verifying the effect of suppressing off-target effects by adding cytosines to the 5' end of the spacer sequence. Under the same conditions as in Figure 9B, the number of cytosines added to the 5' end of the spacer sequence was set to 0, 5, 10, 15, 20, 25, or 30. [Figure 10A] 10A to 10C show the results of a test for repairing a genetic disease mutation in fibrodysplasia ossificans progressiva (FOP). FIG 10A shows an outline of a method for repairing a genetic disease mutation in FOP. [Figure 10B] FIG. 10B shows the results of evaluating the efficiency of HDR induction when HDR was induced to repair the mutant allele (R206H) using human iPS cells having an FOP genetic disease mutation (wt / R206H). [Figure 10C] Figure 10C shows the results of evaluating the efficiency of indel introduction by genome editing targeting the mutant allele (R206H) in human iPS cells carrying the FOP genetic disease mutation (wt / R206H). [Figure 11A] 11A to 11D show the results of a test for producing an FOP genetic disease model. Fig. 11A shows an outline of a method for inducing a mutation in an FOP genetic disease. [Figure 11B]FIG. 11B shows the results of evaluating the efficiency of HDR induction when HDR was induced to induce a mutant allele (R206H) using mouse ES cells (wt / wt). [Figure 11C] Figure 11C shows the results of evaluating the efficiency of indel introduction by genome editing targeting the Acvr1 gene (wt) in mouse ES cells (wt / wt). [Figure 11D] FIG. 11D is a photograph showing an abnormal bone (arrow) formed in a chimeric mouse generated by microinjecting mouse ES cells carrying the FOP genetic disease mutation (wt / R206H) generated by HDR induction into mouse fertilized eggs. [Figure 12A] FIG. 12A shows the results of a cytotoxicity evaluation test using AIMS. [Figure 12B] Figure 12B shows the results of a cytotoxicity evaluation test involving genome editing targeting ACVR1. [Figure 13A] The graph plots the P-value calculated from 253 data points by AIMS on the horizontal axis and the proportion of bilateral indels (Bi; top panel), unilateral indels (Mono; middle panel), and no indels (Nono; bottom panel) on the vertical axis. [Figure 13B] The formula obtained from the graph in Figure 13A shows the results of predicting the proportion of bilateral allele indels (Bi; upper figure), unilateral allele indels (Mono; middle figure), and no indels (None; lower figure). The actual measured values ​​(horizontal axis) and the predicted values ​​(vertical axis) by the formula showed a high correlation. [Figure 13C] The results of genome editing using Cdh1-P2A-AIMS as a target for P2A are shown. The upper figure shows actual data when genome editing was performed using Cdh1-P2A-AIMS as a target for P2A. The middle figure shows a prediction graph created from the obtained data by applying the P value calculated by the above formula (1) to the formula (P=x) in FIG. 13A. The lower figure shows an indel pattern prediction graph obtained based on the method for predicting genome editing patterns according to one embodiment of the present invention. [Figure 14A]An outline of the compound heterozygous construction method is shown. The target positions of P2A-sgRNA1 and Cdh1-sgRNA4 are shown. [Figure 14B] The outline of the compound heterozygous construction method is shown. The genome structure after genome editing using P2A-sgRNA1 and Cdh1-sgRNA4 and the annealing positions of each primer are shown. [Figure 15] The results of an in vitro cleavage assay using sgRNAs with 0, 10, or 25 cytosines are shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] [Definition] As used herein, the terms "polynucleotide" and "nucleic acid" are used interchangeably and refer to a nucleotide polymer in which nucleotides are linked by phosphodiester bonds. A "polynucleotide" and a "nucleic acid" may be DNA, RNA, or a combination of DNA and RNA. A "polynucleotide" and a "nucleic acid" may be a polymer of natural nucleotides, a polymer of natural nucleotides and non-natural nucleotides (such as analogs of natural nucleotides, nucleotides in which at least one of the base moiety, sugar moiety, and phosphate moiety has been modified (e.g., phosphorothioate backbone), etc.), or a polymer of non-natural nucleotides. In this specification, the base sequence of a "polynucleotide" or "nucleic acid" is described in the generally accepted single letter code unless otherwise specified. Unless otherwise specified, the base sequence is described from the 5' to the 3' end. As used herein, nucleotide residues constituting a "polynucleotide" or a "nucleic acid" may be simply described as adenine, thymine, cytosine, guanine, uracil, or the like, or as their single-letter codes.

[0013] As used herein, the term "gene" refers to a polynucleotide that contains at least one open reading frame that encodes a particular protein. A gene can include both exons and introns.

[0014] As used herein, the terms "polypeptide", "peptide" and "protein" are used interchangeably and refer to a polymer of amino acids linked by amide bonds. A "polypeptide", "peptide" or "protein" may be a polymer of natural amino acids, a polymer of natural and non-natural amino acids (such as chemical analogues or modified derivatives of natural amino acids), or a polymer of non-natural amino acids. Unless otherwise specified, amino acid sequences are written from the N-terminus to the C-terminus.

[0015] As used herein, the term "allele" refers to a pair of genes present at the same locus on a pair of chromosomes or a pair of base sequences present at the same locus. The pair of genes is not necessarily alleles, and the pair of base sequences is not necessarily different base sequences. The term "bilateral allele" refers to both of the pair of genes or pair of base sequences, and the term "unilateral allele" refers to either one of the pair of genes or pair of base sequences.

[0016] As used herein, the term "genome editing" refers to the induction of a mutation at a desired position (target region) on a genome. Genome editing may include the use of a nuclease engineered to cleave DNA in a target region. Typically, a double-strand break (DSB) is induced in the DNA of the target region by the use of a site-specific nuclease, and the genome is then repaired by endogenous processes of the cell, such as Homologous Directed Repair (HDR) and Non-Homologous End-Joining Repair (NHEJ). NHEJ is a repair method that joins the ends of a double-strand break without using a repair template DNA, and insertions and / or deletions (indels) are frequently induced during repair. HDR is a repair mechanism that uses a repair template DNA, and it is also possible to introduce a desired mutation into a target region. A preferred example of a genome editing technique is the CRISPR / Cas system.

[0017] As used herein, the term "repair template DNA" refers to DNA used to repair a double-stranded break in DNA, which is capable of homologous recombination with the DNA surrounding the target region. In the present specification, the term "donor vector" refers to a foreign DNA used as a repair template DNA. The donor vector contains a base sequence adjacent to the target region as a homology arm. In the present specification, a homology arm consisting of a base sequence adjacent to the 5' side of the target region may be referred to as a "5' arm", and a homology arm consisting of a base sequence adjacent to the 3' side of the target sequence may be referred to as a "3' arm". The donor vector may contain a desired base sequence between the 5' arm and the 3' arm. The length of each homology arm is preferably 3 kb or more, and is usually about 5 to 10 kb. The lengths of the 5' arm and the 3' arm may be the same or different, but are preferably the same.

[0018] As used herein, the term "safe harbor region" refers to a region in the genome where it has been demonstrated that foreign DNA can be inserted without adverse effects on cells. Examples of safe harbor regions include AAVS1 in humans and Rosa26 in mice.

[0019] As used herein, the term "Cas protein" refers to a CRISPR-associated protein. In a preferred embodiment, the Cas protein forms a complex with a guide RNA and exhibits endonuclease activity or nickase activity. Examples of Cas proteins include, but are not limited to, Cas9 protein, Cpf1 protein, C2c1 protein, C2c2 protein, and C2c3 protein. Cas proteins include wild-type Cas proteins and their homologs (paralogs and orthologs), as well as their mutants, so long as they cooperate with a guide RNA to exhibit endonuclease activity or nickase activity. In a preferred embodiment, the Cas protein is involved in a class 2 CRISPR / Cas system, more preferably in a type II CRISPR / Cas system. A preferred example of the Cas protein is the Cas9 protein.

[0020] As used herein, the term "Cas9 protein" refers to a Cas protein involved in type II CRISPR / Cas system. The Cas9 protein forms a complex with a guide RNA and exhibits activity of cleaving DNA in a target region in cooperation with the guide RNA. The Cas9 protein includes wild-type Cas9 protein and its homologs (paralogs and orthologs), as well as mutants thereof, so long as it has the above-mentioned activity. The wild-type Cas9 protein has a RuvC domain and an HNH domain as nuclease domains, but the Cas9 protein in the present specification may have either the RuvC domain or the HNH domain inactivated. The species of organism from which the Cas9 protein is derived is not particularly limited, and preferred examples include bacteria belonging to the genus Streptococcus, Staphylococcus, Neisseria, or Treponema. More specifically, preferred examples include Cas9 proteins derived from S. pyogenes, S. thermophilus, S. aureus, N. meningitidis, or T. denticola. In a preferred embodiment, the Cas9 protein is a Cas9 protein derived from S. pyogenes.

[0021] Information on the amino acid sequences of various Cas proteins and their coding sequences can be obtained from various databases such as GenBank and UniProt. For example, the amino acid sequence of the Cas9 protein of S. pyogenes registered in UniProt under the accession number Q99ZW2 can be used. An example of the coding sequence of the Cas9 protein of S. pyogenes is shown in SEQ ID NO: 9. The base sequence shown in SEQ ID NO: 9 has 3×Flag and a nuclear localization signal added to the 5' end of the Cas9 protein of S. pyogenes and a nuclear localization signal added to the 3' end.

[0022] As used herein, the terms "guide RNA" and "gRNA" are used interchangeably and refer to an RNA that can form a complex with a Cas protein and guide the Cas protein to a target region. In a preferred embodiment, the guide RNA includes a CRISPR RNA (crRNA) and a trans-activating CRISPR RNA (tracrRNA). The crRNA is involved in binding to a target region on a genome, and the tracrRNA is involved in binding to a Cas protein. In a preferred embodiment, the crRNA includes a spacer sequence and a repeat sequence, and the spacer sequence binds to a complementary strand of the target sequence in the target region. In a preferred embodiment, the tracrRNA includes an anti-repeat sequence and a 3' tail sequence. The anti-repeat sequence has a sequence complementary to the repeat sequence of the crRNA and forms a base pair with the repeat sequence, and the 3' tail sequence usually forms three stem loops. The guide RNA may be a single-stranded guide RNA (sgRNA) in which the 5' end of the tracrRNA is linked to the 3' end of the crRNA, or the crRNA and the tracrRNA may be separate RNA molecules in which the repeat sequence and the anti-repeat sequence form base pairs. In a preferred embodiment, the guide RNA is an sgRNA.

[0023] The repeat sequence of the crRNA and the sequence of the tracrRNA can be appropriately selected depending on the type of Cas protein, and those derived from the same bacterial species as the Cas protein can be used. For example, when using the Cas9 protein derived from S. pyogenes, the length of the sgRNA can be about 50 to 220 nucleotides (nt), preferably about 60 to 180 nt, and more preferably about 80 to 120 nt. The length of the crRNA can be about 25 to 70 bases including the spacer sequence, preferably about 25 to 50 nt. The length of the tracrRNA can be about 10 to 130 nt, preferably about 30 to 80 nt. The repeat sequence of the crRNA may be the same as that in the bacterial species from which the Cas protein is derived, or may be one in which a part of the 3' end has been deleted. The tracrRNA may have the same sequence as the mature tracrRNA in the bacterial species from which the Cas protein is derived, or may be a truncated form in which the 5' end and / or the 3' end of the mature tracrRNA has been truncated. For example, the tracrRNA may be a truncated form in which about 1 to 40 nucleotide residues have been removed from the 3' end of the mature tracrRNA. The tracrRNA may also be a truncated form in which about 1 to 80 nucleotide residues have been removed from the 5' end of the mature tracrRNA. The tracrRNA may also be a truncated form in which, for example, about 1 to 20 nucleotide residues have been removed from the 5' end and about 1 to 40 nucleotide residues have been removed from the 3' end. Various crRNA repeat sequences and tracrRNA sequences for sgRNA design have been proposed, and those skilled in the art can design sgRNAs based on known techniques (e.g., Jinek et al. (2012) Science, 337, 816-21; Mali et al. (2013) Science, 339: 6121, 823-6; Cong et al. (2013) Science, 339: 6121, 819-23; Hwang et al. (2013) Nat. Biotechnol. 31: 3, 227-9; Jinek et al. (2013) eLife, 2, e00471).

[0024] As used herein, the term "target sequence" refers to a DNA sequence in a genome that is to be cleaved by a Cas protein. When a Cas9 protein is used as the Cas protein, the target sequence must be adjacent to the 5' side of a protospacer adjacent motif (PAM). The target sequence is usually selected as a sequence of 17 to 30 bases (preferably 18 to 25 bases, more preferably 19 to 22 bases, and even more preferably 20 bases) adjacent to and immediately before the 5' side of the PAM. A known design tool such as CRISPR DESIGN (crispr.mit.edu / ) can be used to design the target sequence.

[0025] As used herein, the term "target region" refers to a genomic region that includes a target sequence and its complementary strand.

[0026] As used herein, the terms "protospacer adjacent motif" and "PAM" are used interchangeably and refer to a sequence recognized by a Cas protein during DNA cleavage by the Cas protein. The sequence and position of the PAM vary depending on the type of Cas protein. For example, in the case of a Cas9 protein, the PAM must be immediately adjacent to the 3' side of the target sequence. The sequence of the PAM corresponding to the Cas9 protein varies depending on the bacterial species from which the Cas9 protein is derived. For example, the PAM corresponding to the Cas9 protein of S. pyogenes is "NGG", the PAM corresponding to the Cas9 protein of S. thermophilus is "NNAGAA", the PAM corresponding to the Cas9 protein of S. aureus is "NNGRRT" or "NNGRR(N)", the PAM corresponding to the Cas9 protein of N. meningitidis is "NNNNGATT", and the PAM corresponding to the Cas9 protein of T. denticola is "NAAAAC" (where "R" is A or G; "N" is A, T, G, or C).

[0027] In the present specification, the terms "spacer sequence" and "guide sequence" are used interchangeably and refer to a sequence contained in a guide RNA that can bind to a complementary strand of a target sequence. Usually, the spacer sequence is the same sequence as the target sequence (however, T in the target sequence becomes U in the spacer sequence). In an embodiment of the present invention, the spacer sequence may contain one or more base mismatches with the target sequence. When multiple base mismatches are contained, the mismatches may be present at adjacent positions or may be present at distant positions. In a preferred embodiment, the spacer sequence may contain 1 to 5 base mismatches with the target sequence. In a particularly preferred embodiment, the spacer sequence may contain one base mismatch with the target sequence. In the guide RNA, the spacer sequence is located 5' of the crRNA.

[0028] As used herein, the term "mismatch" refers to the inclusion of a base in a spacer sequence that is different from a target sequence, or the difference in base. For example, "the spacer sequence includes a one-base mismatch" means that the spacer sequence is different by one base compared to the target sequence.

[0029] As used herein, the term "indel" refers to an insertion and / or deletion. As used herein, the term "bilateral indel" refers to a state in which an indel is generated in a bilateral target region by genome editing. As used herein, the term "uniallelic indel" refers to a state in which an indel has been generated in only one allele of a target region by genome editing. As used herein, the term "frameshift indel" refers to an indel that results in a frameshift. As used herein, the term "in-frame indel" refers to an indel that does not result in a frameshift.

[0030] As used herein, the term "AIMS" means Allele-specific Indel Monitor System and refers to a technology that can detect indels in an allele-specific manner. As used herein, the term "AIMS cells" refers to cells constructed for performing AIMS and refers to cells capable of detecting indels in an allele-specific manner.

[0031] As used herein, the term "chimeric gene" refers to a polynucleotide in which the coding sequences for two or more different proteins are linked in frame. The term "chimeric protein" refers to a protein expressed from a chimeric gene.

[0032] As used herein, the term "localized protein" refers to a protein that is localized to a certain part of a cell (e.g., the nucleus or cell membrane). A "nuclear-localized protein" refers to a protein that is localized to the nucleus, and a "cell membrane-localized protein" refers to a protein that is localized to the cell membrane.

[0033] The term "cleavage site" as used herein refers to an amino acid or nucleotide sequence that directs cleavage, for example because it can be recognized and / or cleaved by a cleavage enzyme. Typically, at a cleavage site, a polypeptide chain is cleaved by hydrolysis of one or more peptide bonds linking the amino acids. Also, at a cleavage site, a polynucleotide chain is cleaved by hydrolysis of one or more phosphodiester bonds between nucleotides. Cleavage of peptide or phosphodiester bonds may result from chemical or enzymatic cleavage. Enzymatic cleavage refers to the cleavage of a polynucleotide, which in the case of a polynucleotide chain is achieved, for example, by a restriction endonuclease (e.g., type I, type II, type III, type IV or artificial restriction enzyme). In the case of a polypeptide chain, it refers to the cleavage of the polypeptide achieved by proteolytic enzymes, including but not limited to endopeptidases, exopeptidases, or proteases (e.g., serine-proteases, cysteine-proteases, metallo-proteases, threonine-proteases, aspartate-proteases, glutamic acid-proteases). Typically, enzymatic cleavage occurs due to autocleavage or is achieved by an independent proteolytic enzyme. Enzymatic cleavage of a protein or polypeptide can occur either co-translationally or post-translationally. Thus, the term "endopeptidase cleavage site" as used herein refers to a cleavage site within an amino acid sequence where this sequence is cleaved or cleavable by an endopeptidase (e.g., trypsin, pepsin, elastase, thrombin, collagenase, furin, thermolysin, endopeptidase V8, cathepsin). The cleavage site may be cleaved by an autoprotease, i.e., a protease that cleaves a peptide bond within the same protein molecule that also contains a protease. Examples of such autoproteases include the NS2 protease of flaviviruses or the VP4 protease of birnaviruses. Alternatively, the term "cleavage site" refers to an amino acid sequence or a nucleotide sequence that prevents the formation of a peptide bond between amino acids or a phosphodiester bond between nucleotides.For example, peptide bond formation can be hindered due to cotranslational self-processing of polypeptides, resulting in two non-contiguous translation products derived from a single translation event of a single open reading frame. Typically, such self-processing is achieved by "ribosomal skipping" caused by pseudo stop-codon sequences, which induce the translation complex to move from one codon to the next without forming a peptide bond. Examples of sequences that induce ribosomal skipping include, but are not limited to, viral 2A peptides or 2A-like peptides (collectively referred to herein as "2A peptides") used by several families of viruses, including picornaviruses, insect viruses, Aphtoviridae, rotaviruses, and trypanosomes. The best known are the 2A peptides of rhinoviruses and foot-and-mouth disease viruses of the picornavirus family, which are typically used to produce multiple polypeptides from a single ORF. Thus, the term "autocleavage site" as used herein refers to a cleavage site in an amino acid or nucleotide sequence where the sequence is cleaved or cleavable without any additional molecules, or where the formation of a peptide or phosphodiester bond in the sequence is prevented at an initial stage (e.g., via cotranslational autoprocessing as described above). It is understood that the cleavage site typically comprises several amino acids or is encoded by several codons (e.g., in such cases, the "cleavage site" is not translated into a protein but causes translational interference). Thus, the cleavage site also serves the purpose of a peptide linker, i.e., sterically separating two peptides. Thus, in some embodiments, the "cleavage site" is both a peptide linker and provides the cleavage function described above. In this embodiment, the cleavage site may include additional N- and / or C-terminal amino acids.

[0034] As used herein, the term "2A peptide" refers to a viral 2A peptide or a 2A-like peptide. A 2A peptide is a peptide that is cleaved by a peptidase or a ribosomal skip mechanism. Examples of 2A peptides include a 2A peptide (F2A) derived from a foot-and-mouth disease virus (FMDV), a 2A peptide (E2A) derived from an equine rhinitis A virus (ERAV), a 2A peptide (P2A) derived from a porcine teschovirus (PTV-1), and a 2A peptide (T2A) derived from a Thosea asigna virus (TaV).

[0035] As used herein, the term "genome editing pattern" refers to the induction state of genome editing in each allele of the target region of a cell that has been subjected to genome editing. That is, it refers to a state in which genome editing is induced in both alleles or only in one allele.

[0036] As used herein, the term "operably linked" in reference to a polynucleotide means that a first base sequence is positioned sufficiently close to a second base sequence that the first base sequence can affect the second base sequence or a region under the control of the second base sequence. For example, a polynucleotide being operably linked to a promoter means that the polynucleotide is linked so as to be expressed under the control of the promoter.

[0037] As used herein, the term "expressible state" refers to a state in which a polynucleotide can be transcribed in a cell into which the polynucleotide has been introduced. As used herein, the term "expression vector" refers to a vector containing a target polynucleotide and equipped with a system that allows the target polynucleotide to be expressed in a cell into which the vector is introduced. For example, "Cas protein expression vector" refers to a vector that can express Cas protein in a cell into which the vector is introduced. Also, for example, "guide RNA expression vector" refers to a vector that can express guide RNA in a cell into which the vector is introduced.

[0038] As used herein, the term "silent mutation" refers to a genetic mutation that does not change the amino acid sequence of the encoded protein.

[0039] In the present specification, the sequence identity (or homology) between base sequences or between amino acid sequences is determined by aligning two base sequences or amino acid sequences with gaps at the insertion and deletion sites so that the corresponding bases or amino acids are most commonly identical, and calculating the ratio of the identical bases or amino acids to the entire base sequence or the entire amino acid sequence excluding the gaps in the alignment obtained. The sequence identity between base sequences or amino acid sequences can be determined using various homology search software known in the art. For example, the value of sequence identity between base sequences can be obtained by calculation based on the alignment obtained by the known homology search software BLASTN, and the value of sequence identity between amino acid sequences can be obtained by calculation based on the alignment obtained by the known homology search software BLASTP.

[0040] [Method for producing cells with single-allele genome editing] In one embodiment, the present invention relates to a method for producing a nucleic acid sequence comprising the steps of: (A) (a1) a guide RNA having one or more nucleotide residues added to the 5' end of a spacer sequence; (a2) a guide RNA including a spacer sequence having a mismatch of one or more bases with respect to a target sequence; and (a3) ​​an expression vector for the guide RNA of (a1) or (a2); (B) Provided is a method for producing a cell in which only one allele has been genome-edited, the method comprising the step of introducing into a cell at least one selected from the group consisting of a Cas protein and an expression vector thereof.

[0041] <(A) Guide RNA> The manufacturing method of this embodiment uses (a1) a guide RNA having one or more nucleotide residues added to the 5' end of a spacer sequence, (a2) a guide RNA including a spacer sequence having a mismatch of one or more bases with respect to a target sequence, and (a3) ​​at least one selected from the group consisting of an expression vector for the guide RNA of (a1) or (a2).

[0042] <Guide RNA of (a1)> The guide RNA (a1) is a guide RNA in which one or more nucleotide residues are added to the 5' end of the spacer sequence. By performing genome editing using the guide RNA, the rate of genome editing in only one allele is improved, and cells in which only one allele is genome edited can be produced.

[0043] The spacer sequence is not particularly limited as long as it is a spacer sequence that targets any target sequence. The length of the spacer sequence is sufficient as long as it corresponds to the target sequence, and a sequence of 17 to 30 bases, preferably 18 to 25 bases, more preferably 19 to 21 bases, and even more preferably 20 bases is selected. Usually, the spacer sequence is the same as the target sequence (however, "T" in the target sequence becomes "U" in the spacer sequence), but may have a mismatch as long as it has the ability to bind to the complementary strand of the target sequence. In general, a mismatch on the 5' side of the spacer sequence is tolerable. In the production method of this embodiment, a spacer sequence having a one-base mismatch with the target sequence is preferred, such as the guide RNA of (a2) described below.

[0044] The number of nucleotide residues added to the 5'-end of the spacer sequence (hereinafter, sometimes referred to as "added nucleotide residues") is 1 or more, and is not particularly limited, but may be in the range of 1 to 50. The number of added nucleotide residues can be appropriately set according to the type of spacer sequence. For example, the number of added nucleotide residues can be 5 or more, 10 or more, 15 or more, 20 or more, or 25 or more. When the number of added nucleotide residues is equal to or more than the lower limit, the proportion of genome editing performed by only one allele can be further increased. The upper limit of the number of added nucleotide residues is not particularly limited, but can be, for example, 50 or less, preferably 40 or less, and more preferably 35 or less, since the proportion of genome editing performed by only one allele does not change. A preferred range of the number of added nucleotide residues is, for example, 5 to 50, and preferably 5 to 40, 5 to 35, 10 to 40, 10 to 35, 15 to 35, or 20 to 30.

[0045] The type of added nucleotide residue is not particularly limited, but may be, for example, all the same nucleotide residue. For example, the added nucleotide residue may be selected from the group consisting of polyadenine (polyA), polyuracil (polyU), polycytosine (polyC), and polyguanine (polyG). Among them, the type of added nucleotide residue is preferably polyC (all cytosine residues) or polyG (all guanine residues), more preferably polyC, since the rate of genome editing with only one allele is improved. When using an expression vector encoding the guide RNA (a1) like the expression vector (a3) ​​described below, the added polynucleotide residues do not usually contain a complementary sequence of a terminator sequence that stops transcription from the promoter used. For example, when using the U6 promoter, the transcription stops when five consecutive thymines are present, so the added nucleotide residues do not usually contain a sequence of five or more consecutive uracils.

[0046] <Guide RNA of (a2)> The guide RNA (a2) is a guide RNA that includes a spacer sequence having one or more mismatches with the target sequence. By performing genome editing using the guide RNA, the rate of genome editing in only one allele is improved, and cells in which only one allele is genome-edited can be produced.

[0047] The spacer sequence of the guide RNA (a2) has one or more base mismatches with any target sequence. The multiple base mismatches are, for example, 2 to 5 base mismatches, preferably 2 to 4 base mismatches, more preferably 2 or 3 base mismatches, and even more preferably 2 base mismatches. The length of the spacer sequence is the same as that of the guide RNA (a1) above, but is particularly preferably 20 bases. The position where the spacer sequence has one or more mismatches with respect to the target sequence is not particularly limited. For example, when the spacer sequence has 20 bases, the mismatch may be present at any of the 1st to 20th bases counted from the 3'-end to the 5'-end, and may have a mismatch at, for example, the 1st to 17th bases. When the spacer sequence has one mismatch in the above range, the rate of genome editing with only one allele can be further increased. As an example, the spacer sequence may have a mismatch at one or more bases selected from the group consisting of the 2nd to 6th, 8th to 9th, and 15th to 17th bases counted from the 3'-end to the 5'-end.

[0048] The base in the mismatched base is not particularly limited as long as it is different from the base in the target sequence. For example, if the base in the target sequence is a purine base (adenine or guanine), the mismatched base in the spacer sequence can be a pyrimidine base (cytosine or uracil). Similarly, if the base in the target sequence is a pyrimidine base (cytosine or thymine), the mismatched base in the spacer sequence can be a purine base (adenine or guanine). For example, the mismatched base in the spacer sequence can be uracil if the base in the target sequence is adenine, adenine if the base in the target sequence is thymine, cytosine if the base in the target sequence is guanine, and guanine if the base in the target sequence is cytosine.

[0049] <<Guide RNA (a12) having characteristics of (a1) and (a2)>> The guide RNA used in the manufacturing method of this embodiment may have both the features of the guide RNA (a1) and (a2) above. That is, the guide RNA may be a spacer sequence having one or more nucleotide residues added to the 5' end of the spacer sequence, and the spacer sequence has one or more mismatches with the target sequence. By combining the above features (a1) and (a2), the rate of genome editing with only one allele can be improved. The number and type of added nucleotide residues are the same as those listed in the above "Guide RNA of (a1)". In addition, the position and type of mismatched bases are the same as those listed in the above "Guide RNA of (a2)".

[0050] <(a3) Guide RNA expression vector> In the manufacturing method of this embodiment, instead of the guide RNA of (a1), (a2) or (a12), an expression vector of the guide RNA of (a1), (a2) or (a12) may be used. In a preferred embodiment, the manufacturing method of this embodiment uses an expression vector of the guide RNA of (a1), (a2) or (a12).

[0051] The expression vector of the guide RNA (a1), (a2) or (a12) above preferably comprises a sequence encoding the guide RNA (a1), (a2) or (a12) above and a promoter that controls the expression of the guide RNA coding sequence. In the expression vector, the guide RNA coding sequence is operably linked to the promoter.

[0052] The promoter is not particularly limited, and for example, a pol II promoter can be used. From the viewpoint of more accurate transcription of a relatively short RNA, however, a pol II promoter is preferred. Pol III promoters are preferred. Examples of pol III promoters include, but are not limited to, mouse and human U6-snRNA promoters, human H1-RNase P RNA promoters, and human valine-tRNA promoters. When using the U6 promoter, it is preferable that the 5' end of the guide RNA is "G" for transcription initiation. Therefore, when the guide RNA is the guide RNA of (a1) or (a12) above, it is preferable to further add "G" to the 5' end of the 5 to 50 nucleotide residues added to the 5' end of the spacer sequence. In addition, when the guide RNA is the guide RNA of (a2) above, it is preferable to select a spacer sequence whose 5' end is "G" or to add "G" to the 5' end of the spacer sequence.

[0053] In addition to the coding sequence and promoter of the guide RNA, the expression vector may contain an enhancer, a polyA addition signal, a marker gene, a replication origin, a gene encoding a protein that binds to the replication origin and controls replication, and the like, if desired. The term "marker gene" refers to a gene that enables cell sorting or selection by introducing the marker gene into a cell. Specific examples of the marker gene include drug resistance genes, fluorescent protein genes, luminescent enzyme genes, and chromogenic enzyme genes. These may be used alone or in combination of two or more. Specific examples of the drug resistance genes include puromycin resistance genes, geneticin resistance genes, neomycin resistance genes, tetracycline resistance genes, kanamycin resistance genes, zeocin resistance genes, hygromycin resistance genes, and chloramphenicol resistance genes. Specific examples of the fluorescent protein genes include green fluorescent protein (GFP) genes, yellow fluorescent protein (YFP) genes, and red fluorescent protein (RFP) genes. Specific examples of the luminescent enzyme genes include luciferase genes, and the like. Specific examples of the chromogenic enzyme gene include a β-galactosidase gene, a β-glucuronidase gene, and an alkaline phosphatase gene.

[0054] The type of expression vector is not particularly limited, and any known expression vector can be used. Examples of expression vectors include plasmid vectors and viral vectors.

[0055] The plasmid vector is not particularly limited as long as it can be expressed in the cell to be genome-edited. For example, in the case of an animal cell, a plasmid vector generally used for animal cell expression can be used. Examples of the plasmid vector for animal cell expression include, but are not limited to, pX459, pA1-11, pXT1, pRc / CMV, pRc / RSV, pcDNAI / Neo, etc.

[0056] Examples of viral vectors include retroviral (including lentiviral) vectors, adenoviral vectors, adeno-associated viral vectors, Sendai viral vectors, herpes viral vectors, vaccinia viral vectors, pox viral vectors, polio viral vectors, Silvis viral vectors, rhabdo viral vectors, paramyxo viral vectors, and orthomyxo viral vectors.

[0057] Among these, the expression vector is preferably a plasmid vector.

[0058] <(B) Cas protein> <Cas Protein> The Cas protein is not particularly limited as long as it is used in the CRISPR / Cas system. For example, various Cas proteins can be used that form a complex with a guide RNA, are guided to a target region by the guide RNA, and can perform double-stranded cleavage of DNA in the target region. In the production method of this embodiment, the Cas protein is preferably a Cas9 protein, and more preferably a Cas9 protein of S. pyogenes.

[0059] The Cas protein may be a mutant of a wild-type Cas protein, so long as it forms a complex with a guide RNA and exhibits endonuclease activity or nickase activity (hereinafter referred to as "Cas protein activity"). Examples of the Cas protein mutant include the following proteins (b1) and (b2). (b1) A protein having an amino acid sequence having, for example, 85% or more, preferably 90% or more, more preferably 95% or more, and even more preferably 98% or more sequence identity to the amino acid sequence of a wild-type Cas protein, and having Cas protein activity. (b2) A protein having an amino acid sequence in which one or more (for example, 2 to 100, preferably 2 to 50, more preferably 2 to 20, even more preferably 2 to 10, still more preferably 2 to 5, and particularly preferably 2) amino acids have been substituted, deleted, added, or inserted relative to the amino acid sequence of a wild-type Cas protein, and which has Cas protein activity.

[0060] <Cas protein expression vector> In the production method of this embodiment, an expression vector for a Cas protein may be used instead of the above-mentioned Cas protein. In a preferred embodiment, the production method of this embodiment uses an expression vector for a Cas protein.

[0061] The expression vector for the Cas protein preferably comprises a coding sequence for the Cas protein and a promoter that controls the expression of the Cas protein coding sequence, wherein the Cas protein coding sequence is operably linked to the promoter in the expression vector.

[0062] The promoter is not particularly limited, and for example, various pol II promoters can be used. Examples of pol II promoters include, but are not limited to, CMV promoter, EF1 promoter, SV40 promoter, MSCV promoter, hTERT promoter, β-actin promoter, CAG promoter, and CBh promoter.

[0063] In addition to the Cas protein coding sequence and promoter, the expression vector may optionally contain an enhancer, a polyA addition signal, a marker gene, a replication origin, a gene encoding a protein that binds to the replication origin to control replication, etc. Examples of the marker gene include those similar to those described above.

[0064] The type of expression vector is not particularly limited, and any known expression vector can be used. Examples of expression vectors include plasmid vectors, viral vectors, etc. Examples of these vectors include the same vectors as those described above. Among these, the expression vector is preferably a plasmid vector.

[0065] The Cas protein coding sequence contained in the expression vector may be codon-optimized according to the species of organism from which the cell into which the expression vector is introduced is derived. In general, codon optimization refers to replacing at least one codon in the original base sequence with a codon that is more frequently used in the target organism while maintaining the original amino acid sequence. The codon usage frequency table can be found, for example, in the "Codon Usage Index" provided by the Kazusa DNA Research Institute, a public interest incorporated foundation. Codon optimization tables are readily available at the Kazusa Database (www.kazusa.or.jp / codon / ) and these tables can be used to optimize codons. Computer algorithms for codon-optimizing specific sequences for expression in specific animal species are also available, for example, at Gene Forge (Aptagen; Jacobus, Pa.).

[0066] The expression vector for the guide RNA and the expression vector for the Cas protein may be the same expression vector. That is, in the production method of this embodiment, an expression vector containing the guide RNA coding sequence and the Cas protein coding sequence in an expressible state can be used. In the expression vector, it is preferable that the guide RNA coding sequence and the Cas protein coding sequence are functionally linked to different promoters.

[0067] <Introduction process> The production method of this embodiment includes the step of introducing (A) the guide RNA (a1), (a2) or (a12) or its expression vector, and (B) a Cas protein or its expression vector into a cell.

[0068] The cells into which (A) and (B) are introduced are not particularly limited, and any desired cell to be the subject of genome editing can be used. The organisms from which the cells are derived are not particularly limited, and include mammals such as humans, monkeys, mice, rats, dogs, cats, rabbits, cows, horses, pigs, goats, and sheep; birds such as chickens; reptiles such as snakes and lizards; amphibians such as African clawed frogs; fish animals such as zebrafish, medaka, and tiger pufferfish; chordates such as ascidians; arthropods such as fruit flies and silkworms; and other animals; plants such as Arabidopsis thaliana, rice, wheat, and tobacco; fungi such as yeast and Neurospora crassa; bacteria such as Escherichia coli, Bacillus subtilis, and blue-green algae. The type of cell is not particularly limited, and examples thereof include cells derived from various tissues or having various properties, such as blood cells, hematopoietic stem cells / progenitor cells, gametes (sperm, eggs), fertilized eggs, fibroblasts, epithelial cells, vascular endothelial cells, nerve cells, hepatic cells, keratinocytes, muscle cells, epidermal cells, endocrine cells, tissue stem cells, iPS cells, ES cells, cancer cells, etc. Also included are cells having various genetic diseases such as sickle cell disease, Huntington's disease, Duchenne muscular dystrophy, fibrodysplasia ossificans progressiva (FOP), etc.

[0069] The above-mentioned introduction methods (A) and (B) are not particularly limited and can be appropriately selected depending on the target cells and the type of material (whether it is a nucleic acid or a protein, etc.). Methods for introducing an expression vector into cells include, for example, lipofection, microinjection, DEAE-dextran, gene gun, electroporation, calcium phosphate, etc. When the expression vector is a viral vector, methods for infecting cells with the viral vector include, for example, the polybrene method.

[0070] The method for introducing RNA into cells is not particularly limited, and any known method can be appropriately selected and used. For example, a commercially available RNA transfection reagent such as Lipofectamine (registered trademark) MessengerMAX (manufactured by Life Technologies) can be used for the RNA.

[0071] The method for introducing a protein into a cell is not particularly limited, and any known method can be appropriately selected and used, such as a method using a protein introduction reagent, a method using a protein introduction domain (PTD) fusion protein, a microinjection method, etc.

[0072] The above (A) and (B) may be introduced into a cell simultaneously, sequentially, or separately with a certain interval between them. In a preferred embodiment, the above (A) and (B) are introduced into a cell simultaneously.

[0073] <Optional process> The production method of this embodiment may include any step in addition to the above-mentioned introduction step, for example, (C) the step of introducing a donor vector into a cell.

[0074] <(C) Donor Vector> The donor vector comprises a base sequence adjacent to the target region as a homology arm. The donor vector may comprise a desired base sequence (hereinafter, sometimes referred to as a "knock-in sequence") between the 5' arm and the 3' arm. The knock-in sequence is not particularly limited and may be any sequence. The knock-in sequence may be, for example, a sequence for gene knockout, a sequence for base substitution, or any gene sequence. When the knock-in sequence is any gene sequence, it is preferable to set the target sequence within the safe harbor region.

[0075] The donor vector may be a circular DNA vector (e.g., a plasmid vector) or a linear DNA vector. The donor vector may contain other sequences in addition to the homology arm and the knock-in sequence. Examples of the other sequences include a marker gene, a replication origin, and a gene encoding a protein that binds to the replication origin and controls replication. Examples of the marker gene include the same as those described above.

[0076] The method of introducing the donor vector is not particularly limited and can be appropriately selected depending on the target cell. Examples of the method of introducing the donor vector into the cell include the lipofection method, the microinjection method, the DEAE dextran method, the gene gun method, the electroporation method, and the calcium phosphate method.

[0077] The donor vector may be introduced into the cell simultaneously with the above (A) and (B), or may be introduced sequentially, or may be introduced at a certain time interval after the introduction of (A) and (B). In a preferred embodiment, the donor vector is introduced into the cell simultaneously with the above (A) and (B).

[0078] ≪Culture process≫ The optional step may be a step of culturing the cells after introducing the above (A) and (B), and, if necessary, the above (C) into the cells. The cell culture may be performed under appropriate culture conditions depending on the type of the cells. When the above (A), (B) and / or (C) are vectors containing a drug resistance marker, the culture may be performed in the presence of the drug. By culturing in the presence of the drug, genome-edited cells can be efficiently selected. In addition, the cells may be cloned by diluting the cell culture solution or plating, etc.

[0079] <Genome editing pattern analysis process> The optional step may be a step of introducing (A) and (B), and, if necessary, (C) into a cell, and then analyzing the genome editing pattern. The method for analyzing the genome editing pattern is not particularly limited, but examples include a method in which, after the above-mentioned introduction step, a culture step is appropriately performed, the cell culture medium is plated, DNA is extracted from the resulting colonies, and the sequence of the target region is analyzed. By performing sequence analysis of the target regions of both alleles, it is possible to confirm whether the cell is a cell in which only one allele has been genome edited.

[0080] In the manufacturing method of this embodiment, the ratio of cells whose genome is edited only with one allele can be increased during genome editing by using, as the guide RNA, (a1) a guide RNA in which one or more nucleotide residues are added to the 5' end of the spacer sequence, or (a2) a guide RNA containing a spacer sequence having one or more mismatches with the target sequence. Therefore, according to the manufacturing method of this embodiment, cells whose genome is edited only with one allele can be efficiently manufactured. In addition, according to the manufacturing method of this embodiment, the cytotoxicity caused by the introduction of sgRNA, Cas9, etc. can be suppressed.

[0081] In another aspect, the present invention provides a method for genome editing of only one allele, comprising the steps of: (A) introducing into a cell at least one selected from the group consisting of (a1) a guide RNA having one or more nucleotide residues added to the 5' end of a spacer sequence, (a2) a guide RNA comprising a spacer sequence having a mismatch of one or more bases with respect to a target sequence, and (a3) ​​an expression vector for the guide RNA of (a1) or (a2); and (B) at least one selected from the group consisting of a Cas protein and an expression vector thereof.

[0082] [Guide RNA, vector, kit] In one embodiment, the present invention provides a guide RNA having one or more nucleotide residues added to the 5' end of the spacer sequence. The guide RNA of this embodiment is the same as the guide RNA (a1) described in the above section [Method for producing cells in which only one allele has been genome-edited] <(A) Guide RNA>. The guide RNA of this embodiment is preferably a sequence in which the spacer sequence has one or more base mismatches with the target sequence, i.e., the guide RNA of (a12) above.

[0083] In one embodiment, the present invention provides an expression vector for a guide RNA having one or more nucleotide residues added to the 5' end of a spacer sequence. The expression vector of this embodiment is similar to the expression vector for the guide RNA (a1) or (a12) described in the above section [Method for producing cells in which only one allele has been genome-edited] <(A) Guide RNA>. The expression vector of this embodiment may further contain a Cas protein coding sequence (preferably a Cas9 protein coding sequence) in an expressible state.

[0084] In one embodiment, the present invention provides a production kit for a cell in which only one allele has been genome-edited, comprising at least one selected from the group consisting of (A) (a1) a guide RNA having one or more nucleotide residues added to the 5'-end of a spacer sequence, (a2) a guide RNA including a spacer sequence having a mismatch of one or more bases with respect to a target sequence, and (a3) ​​an expression vector for the guide RNA of (a1) or (a2). The production kit preferably further comprises (B) at least one selected from the group consisting of a Cas protein and its expression vector. The guide RNAs (a1) and (a2) are the same as the guide RNAs (a1) and (a2) described in the above [Method for producing a cell in which only one allele is genome-edited] <(A) Guide RNA>. The guide RNA may be the guide RNA (a12) described above. The expression vector of (a3) ​​is the same as the expression vector of the guide RNA of (a3) ​​described in the above section [Method for producing cells in which only one allele has been genome-edited] <(A) Guide RNA>. The (B) Cas protein and its expression vector are the same as those described in the above section [Method for producing cells in which only one allele has been genome-edited] <(B) Cas protein>. When (A) and (B) are expression vectors, the guide RNA coding sequence and the Cas protein coding sequence may be contained in the same expression vector in an expressible state. The kit of this embodiment may have other configurations in addition to the above (A) and (B). The other configurations are not particularly limited, and examples thereof include instructions for producing cells in which only one allele has been genome-edited, and reagents used for introducing an expression vector into cells.

[0085] [Method for predicting genome editing patterns] In one embodiment, the present invention provides a method for predicting a genome editing pattern, comprising: (i) introducing a guide RNA or an expression vector thereof, and a Cas protein or an expression vector thereof into a cell to perform genome editing; (ii) extracting DNA from the cell in which the genome editing has been performed; (iii) amplifying a DNA fragment containing a target region from the DNA; (iv) analyzing the sequence of the amplified DNA fragment to determine an indel induction rate (P) for the target region; and (v) calculating the indel induction rate for only one allele (mono) and the indel induction rate for both alleles (bi) using the following formula (m) or (m1) and (b) or (b1). mono = 2 × P × (1-P) (m) bi=P 2 (b) mono=-1.303P 2 +1.2761P+0.0274 ···(m1) bi=0.6515P 2 +0.3619P-0.0137 ···(b1)

[0086] <Process (i)> Step (i) is a step of introducing a guide RNA or its expression vector, and a Cas protein or its expression vector into a cell to perform genome editing.

[0087] The guide RNA is not particularly limited, and any guide RNA that can be used in the CRISPR / Cas system may be used. The spacer sequence is not particularly limited, and any spacer sequence that targets any target sequence may be used. The expression vector for the guide RNA can be prepared in the same manner as the expression vector described in the above section [Method for producing cells in which only one allele has been genome-edited] <(A) Guide RNA>.

[0088] The Cas protein is not particularly limited, and any Cas protein that can be used in the CRISPR / Cas system may be used. The Cas protein is preferably the Cas9 protein, and more preferably the Cas9 protein of S. pyogenes. The expression vector for the Cas protein can be prepared in the same manner as the expression vector described in the above section [Method for producing cells in which only one allele has been genome-edited] <(B) Cas protein>.

[0089] The guide RNA and Cas protein, or their expression vectors, can be introduced into cells in the same manner as described in <Introduction step> in [Method for producing cells in which only one allele has been genome-edited] above. After the introduction into the cells, the cells may be cultured as appropriate. When an expression vector for a guide RNA and a Cas protein is introduced into the cells and the expression vector has a drug resistance marker, the cells may be cultured in the presence of the drug to select the cells into which the expression vector has been introduced.

[0090] <Process (ii)> Step (ii) is a step of extracting DNA from the cells that have undergone genome editing in step (i).

[0091] The method for extracting DNA is not particularly limited, and any known DNA extraction method may be used. Examples of the DNA extraction method include the phenol-chloroform extraction method and the method of heating under alkaline conditions (e.g., 99°C for 10 minutes in the presence of 50 mM NaOH). Commercially available DNA extraction kits can also be used.

[0092] <Step (iii)> Step (iii) is a step of amplifying a DNA fragment containing a target region from the DNA extracted in step (ii).

[0093] The method for amplifying the target region is not particularly limited, and any known nucleic acid fragment amplification method may be used. Examples of the nucleic acid fragment amplification method include PCR and isothermal amplification. For example, a primer capable of amplifying the target region can be designed, and the DNA fragment of the target region can be amplified by PCR or isothermal amplification. The length of the amplified DNA fragment is not particularly limited as long as it contains the target region, but can be, for example, about 20 to 1000 bp, usually about 350 to 750 bp.

[0094] The amplified DNA fragment may be cloned using a commercially available cloning vector or the like. Furthermore, the cloning vector into which the amplified DNA fragment is inserted may be introduced into Escherichia coli or the like, and the Escherichia coli may be cultured to form colonies. DNA may be extracted from the colonies thus obtained and subjected to sequence analysis in step (iv). The number of colonies to be subjected to sequence analysis is not particularly limited, and may be, for example, about 10 to 200, about 20 to 100, or about 20 to 50, etc.

[0095] <Process (iv)> Step (iv) is a step of analyzing the sequence of the DNA fragment amplified in step (iii) to determine the indel induction rate (P) in the target region.

[0096] The method of sequence analysis of DNA fragments is not particularly limited, and known sequence analysis methods may be used. For sequence analysis, a commercially available sequencer may be used, and DNA sequencing may be performed according to the method recommended by the manufacturer. In addition, the presence or absence of indels in the amplified DNA fragments may be analyzed by T7E1 assay, or sequence analysis by a sequencer and T7E1 assay may be used in combination.

[0097] The indel induction rate (P) in the target region can be calculated based on the results of sequence analysis using the following formula (p):

[0098]

number

[0099] <Process (v)> Step (v) is a step of calculating the indel induction rate for only one allele (mono) and the indel induction rate for both alleles (bi) using the following formulas (m) and (b). mono = 2 × P × (1-P) (m) bi=P 2 (b)

[0100] The following formulas (m1) and (b1) may be used instead of the above formulas (m) and (b). mono=-1.303P 2 +1.2761P+0.0274 ···(m1) bi=0.6515P 2 +0.3619P-0.0137 ···(b1)

[0101] By substituting the value of the indel induction rate (P) obtained in step (iv) into the above formula (m) or (m1) and (b) or (b1), the indel induction rate for only one allele (mono) and the indel induction rate for both alleles (bi) can be obtained. As shown in the examples described later, the values ​​of the indel induction rate (mono) and the indel induction rate (bi) obtained by the method of this embodiment are close to the respective indel induction rates confirmed by actual tests.

[0102] According to the prediction method of the present embodiment, the indel induction rate for only one allele and the indel induction rate for both alleles can be predicted by a simple operation. Therefore, by carrying out the prediction method of the present embodiment using any guide RNA, the genome editing pattern by genome editing using the guide RNA can be predicted.

[0103] [AIMS cells] In one embodiment, the present invention provides a cell comprising a chimeric gene in which a localization protein coding sequence, a cleavage site coding sequence, and a first fluorescent protein coding sequence are linked in frame in this order in one allele, and a chimeric gene in which the localization protein coding sequence, the cleavage site coding sequence, and a second fluorescent protein coding sequence are linked in frame in this order in the other allele. Note that the terms "first" and "second" are used herein for convenience.

[0104] The cells of this embodiment are cells (AIMS cells) that can be used for analyzing genome editing patterns by AIMS, which will be described later. By using the cells of this embodiment, it is possible to easily examine whether genome editing is induced by both alleles or only by one allele.

[0105] <Localization protein coding sequence> The localized protein can be appropriately selected depending on the cell to be the target of genome editing. The localized protein may be a natural protein or an artificial protein (e.g., a mutant protein or a truncated protein of a natural localized protein, a peptide containing a localization signal, etc.) as long as it is a protein that is localized in the cell. When the localized protein is a natural protein, the natural protein may be an endogenous protein of the target cell or an exogenous protein (a localized protein derived from another organism). The localized protein is preferably an endogenous protein of the target cell and is constantly expressed. The localized protein may be a nuclear localized protein or a cell membrane localized protein.

[0106] In the case of human cells, examples of the nuclear localized proteins include various transcription factors and various transcription regulatory factors. Specific examples include the TBX family such as the TBX3 protein, and the SOX family such as the SOX2 protein. Examples of the cell membrane localized proteins include various cell membrane receptors and various cell membrane antigens. Specific examples include the cadherin family such as E-cadherin, and the SSEA family such as SSEA4.

[0107] The localization protein coding sequence is not particularly limited as long as it has a base sequence encoding a localization protein, and may include silent mutations. The localization protein coding sequence may utilize an endogenous gene sequence of an endogenous localization protein, or may be foreign DNA. When the localization protein coding sequence is foreign DNA (e.g., an exogenous natural localization protein coding sequence, an artificial localization protein coding sequence, etc.), the localization protein coding sequence may be functionally linked to a promoter that is constitutively expressed in a target cell.

[0108] <Cut site> The cleavage site is not particularly limited, but may be, for example, an autocleavage site or an endopeptidase cleavage site, and a specific example is the 2A peptide coding sequence. The 2A peptide is not particularly limited, and any known 2A peptide or 2A-like peptide can be used. For example, a 2A peptide selected from the group consisting of P2A peptide, F2A peptide, E2A peptide, and T2A peptide can be used. When the cleavage site encodes an amino acid sequence such as a self-cleavage sequence such as a ribosomal skip or a peptidase recognition sequence, it may contain a silent mutation. For example, the 2A peptide coding sequence is not particularly limited as long as it has a base sequence encoding the 2A peptide, and may contain a silent mutation. In addition, the 2A peptide coding sequence may be codon-optimized according to the target cell. As specific examples of the 2A peptide coding sequence, the P2A peptide coding sequence and the coding sequence (aP2A) containing a silent mutation in the P2A peptide coding sequence are shown in SEQ ID NO: 14 and SEQ ID NO: 15, respectively.

[0109] <First fluorescent protein coding sequence> The first fluorescent protein is not particularly limited, and a known fluorescent protein can be used. Examples of the fluorescent protein include Sirius, BFP, EBFP, ECFP, mTurquoise, TagCFP, AmCyan, mTFP1, MidoriishiCyan, CFP, TurboGFP, AcGFP, TagGFP, Azami-Green, ZsGreen, EmGFP, GFP, EGFP, GFP2, HyPer, TagYFP, EYFP, Venus, YFP, PhiYFP, PhiYFP-m, TurboYFP, ZsYellow, mBanana, KusabiraOrange, and mOran. Examples of such antibodies include, but are not limited to, ge, TurboRFP, tdTomato, DsRed, DsRed-Express, DsRed2, TagRFP, DsRed-Monomer, AsRed, AsRed2, mStrawberry, TurboFP602, RFP, ERFP, mRFP1, JRed, KillerRed, mCherry, HcRed, KeimaRed, TurboFP650, mRasberry, mPlum, PS-CFP, Dendra2, Kaede, EosFP, and KikumeGR.

[0110] The first fluorescent protein coding sequence is not particularly limited as long as it has a base sequence encoding a fluorescent protein, and may include silent mutations. It may also be codon-optimized according to the target cell. Specific examples of fluorescent protein coding sequences are the tdTomato coding sequence and the Venus coding sequence shown in SEQ ID NO: 16 and SEQ ID NO: 17, respectively.

[0111] <Second fluorescent protein coding sequence> The second fluorescent protein is a fluorescent protein different from the first fluorescent protein. The second fluorescent protein is not particularly limited as long as it is different from the first fluorescent protein, and a known fluorescent protein can be used. Examples of the fluorescent protein include those exemplified as the first fluorescent protein. The second fluorescent protein preferably has a different fluorescent wavelength from the first fluorescent protein.

[0112] The second fluorescent protein coding sequence is not particularly limited as long as it has a base sequence encoding a fluorescent protein, and may contain silent mutations or may be codon-optimized according to the target cell.

[0113] <Chimeric gene> The cell of this embodiment contains a chimeric gene (hereinafter, sometimes referred to as "first chimeric gene") in which a localization protein coding sequence, a cleavage site (e.g., 2A peptide coding sequence), and a first fluorescent protein coding sequence are linked in frame in this order in one allele (hereinafter, sometimes referred to as "first chimeric gene"), and a chimeric gene (hereinafter, sometimes referred to as "second chimeric gene") in which a localization protein coding sequence, a cleavage site (e.g., 2A peptide coding sequence), and a second fluorescent protein coding sequence are linked in frame in this order in the other allele (hereinafter, sometimes referred to as "second chimeric gene"). The cleavage sites (e.g., 2A peptide coding sequences) of the first chimeric gene and the second chimeric gene are the same. The localization protein coding sequences of the first chimeric gene and the second chimeric gene are preferably the same.

[0114] In a preferred embodiment, the first chimeric gene and the second chimeric gene are located at the locus of the endogenous localization protein gene of the cell. Alternatively, the first chimeric gene and the second chimeric gene may be located at the same locus within the safe harbor region. The first chimeric gene and the second chimeric gene are present on the first allele and the second allele, respectively, in an expressible state within the cell.

[0115] <Method for producing AIMS cells> AIMS cells containing the above-described first chimeric gene and second chimeric gene can be produced using techniques such as genome editing. Specific examples of the method for producing AIMS cells are described below, but the method is not limited thereto.

[0116] First, donor vectors (knock-in vectors) containing the first chimeric gene and the second chimeric gene are prepared as vectors for knocking in the first chimeric gene and the second chimeric gene into the genome of the target cell. The knock-in vectors can be prepared by known methods. The homology arms can be appropriately designed according to the position on the genome where the chimeric gene is inserted. The homology arms are preferably the nucleotide sequences of the endogenous localization protein gene and the region adjacent to the localization protein gene.

[0117] Next, a guide RNA having a sequence within the region where the chimeric gene is to be knocked in as a target sequence is designed. When the homology arms of the knock-in vector are the nucleotide sequences of the endogenous localization protein gene and the region adjacent to the localization protein gene, the target sequence is selected, for example, from the sequences within the endogenous localization protein gene.

[0118] Then, the guide RNA or its expression vector, the Cas protein or its expression vector, and the knock-in vector of the first chimeric gene and the knock-in vector of the second chimeric gene are introduced into the cell. When the expression vectors of the guide RNA and the Cas protein are used, the expression vectors may be the same. The introduction method can be the same as that described in the above section "Introduction step" in [Method for producing cells in which only one allele has been genome-edited]. After the introduction into the cells, the cells may be cultured as appropriate. When an expression vector for a guide RNA and a Cas protein is introduced into a cell and the expression vector has a drug resistance marker, the cells into which the expression vector has been introduced may be cultured in the presence of the drug to select the cells. When each knock-in vector for the first and second chimeric genes has a drug resistance marker, the cells into which the knock-in vector has been introduced may be cultured in the presence of the drug to select the cells.

[0119] Next, cells in which the fluorescence of both the first fluorescent protein and the second fluorescent protein is observed are collected. Fluorescent cells can be selected by a known method, for example, using a flow cytometer, a fluorescent microscope, or the like. The obtained cells can be confirmed by PCR or the like to confirm that the first chimeric gene and the second chimeric gene are inserted into each of the target loci of the first allele and the second allele, respectively.

[0120] In the cell of this embodiment, the chimeric proteins expressed from the first and second chimeric genes are cleaved at the cleavage site (e.g., 2A peptide). The first and second fluorescent proteins are separated from the localized proteins, and therefore are distributed throughout the cell without being localized within the cell (see FIG. 1A "wt"). On the other hand, if genome editing is performed targeting a cleavage site (e.g., the 2A peptide coding sequence), a frameshift indel occurs at the cleavage site (e.g., the 2A peptide coding sequence), and the fluorescent protein is no longer produced. Therefore, the fluorescence of the fluorescent protein introduced into the allele with the frameshift indel disappears (see Figure 1A "frame-shift"). On the other hand, if genome editing is performed targeting a cleavage site (e.g., the 2A peptide), and an in-frame indel occurs at the cleavage site (e.g., the 2A peptide coding sequence), cleavage at the 2A peptide will not occur. Therefore, the fluorescent protein introduced into the allele with the frameshift indel will be localized according to the localized protein without being separated from the localized protein (see Figure 1A "in-frame").

[0121] The target cells used for producing AIMS cells are not particularly limited, and any desired cells can be used. The organisms from which the cells are derived are not particularly limited, and include mammals such as humans, monkeys, mice, rats, dogs, cats, rabbits, cows, horses, pigs, goats, and sheep; birds such as chickens; reptiles such as snakes and lizards; amphibians such as African clawed frogs; fish such as zebrafish, medaka, and tiger pufferfish; chordates such as ascidians; arthropods such as fruit flies and silkworms; plants such as Arabidopsis thaliana, rice, wheat, and tobacco; fungi such as yeast and Neurospora crassa; and bacteria such as Escherichia coli, Bacillus subtilis, and blue-green algae. The type of target cell is not particularly limited, and examples thereof include cells derived from various tissues or having various properties, such as blood cells, hematopoietic stem cells / progenitor cells, gametes (sperm, eggs), fertilized eggs, fibroblasts, epithelial cells, vascular endothelial cells, nerve cells, hepatic cells, keratinocytes, muscle cells, epidermal cells, endocrine cells, tissue stem cells, iPS cells, ES cells, cancer cells, etc. Also included are cells having various genetic diseases such as sickle cell disease, Huntington's disease, Duchenne muscular dystrophy, etc. The subject cells may be primary cultured cells or immortalized cell lines, such as human HeLa cells, African green monkey COS7 cells, mouse 3T3 cells, hamster CHO cells, and rat PC12 cells.

[0122] In the method for analyzing genome editing patterns described below, the above-mentioned characteristics of the cells of this embodiment are utilized to analyze genome editing patterns.

[0123] [Method of analyzing genome editing patterns] In one embodiment, the present invention provides a method for analyzing a genome editing pattern, comprising: (I) introducing a guide RNA or an expression vector thereof targeting the cleavage site (e.g., a 2A peptide coding sequence) and a Cas protein or an expression vector thereof into a cell of the embodiment (AIMS cell) to perform genome editing; (II) analyzing the fluorescence pattern of the cell after the step (I); and (III) determining the genome editing pattern based on the fluorescence pattern analyzed in the step (II).

[0124] The method for analyzing genome editing patterns of the present embodiment is characterized by using the AIMS cells. By using the AIMS cells, genome editing patterns can be analyzed in a simple manner.

[0125] <Process (I)> Step (I) is a step of performing genome editing by introducing a guide RNA or its expression vector targeting a cleavage site (e.g., a 2A peptide coding sequence) and a Cas protein or its expression vector into AIMS cells.

[0126] The guide RNA targeting the cleavage site (e.g., 2A peptide coding sequence) can be appropriately designed according to the base sequence of the cleavage site (e.g., 2A peptide coding sequence) of the AIMS cell used. For example, when the 2A peptide used as the cleavage site is P2A peptide, the target sequence is exemplified by the sequence shown in SEQ ID NO: 14. The method for introducing the guide RNA or its expression vector, and the Cas protein or its expression vector may be the same as that described in the above section "Introduction step" of [Method for producing cells in which only one allele is genome-edited]. When using expression vectors for the guide RNA and the Cas protein, the expression vectors may be the same. After the introduction into the cells, the cells may be cultured as appropriate. When an expression vector for a guide RNA and a Cas protein is introduced into the cells and the expression vector has a drug resistance marker, the cells may be cultured in the presence of the drug to select the cells into which the expression vector has been introduced. The cells may also be cloned by diluting the cell culture solution or plating.

[0127] <Process (II)> Step (II) is a step of analyzing the fluorescence pattern of the AIMS cells after step (I).

[0128] The analysis of the fluorescence pattern of AIMS cells after genome editing can be performed by a known method. Examples of the analysis method of the fluorescence pattern include observation by a fluorescence microscope and a method using a flow cytometer. From the viewpoint of being able to analyze the fluorescence pattern with high accuracy, for example, observation by a fluorescence microscope is preferred. However, as long as the fluorescence pattern can be analyzed, the analysis method is not particularly limited. The fluorescence patterns that can be detected by this process are shown in Table 1.

[0129] [Table 1]

[0130] <Process (III)> Step (III) is a step of determining the genome editing pattern based on the fluorescence pattern analyzed in step (II).

[0131] Based on the fluorescence pattern analyzed in step (II), the genome editing pattern can be determined as shown in Table 2.

[0132] [Table 2]

[0133] As described above, in the fluorescent patterns (2) and (3), only the second allele is determined to have been genome-edited. In the fluorescent patterns (4) and (7), only the first allele is determined to have been genome-edited. In the fluorescent patterns (5), (6), (8), and (9), both the first and second alleles are determined to have been genome-edited. In the fluorescent pattern (1), it is determined that none of the alleles have been genome-edited.

[0134] According to the method of the present embodiment, genome editing patterns can be analyzed in a simple manner. Furthermore, the genome editing patterns analyzed in individual cells can be compiled, and the proportion of genome editing with both alleles and the proportion of genome editing with only one allele can be obtained. Therefore, for example, it is possible to analyze whether a newly designed guide RNA is likely to induce genome editing with both alleles, or is likely to induce genome editing with only one allele. Therefore, the method of the present embodiment is useful for developing a new guide RNA for inducing a desired genome editing pattern.

[0135] [Treatment, mitigation, and / or prevention of genetic diseases through single-allele genome editing] In one embodiment, the present invention provides treatment, alleviation, and / or prevention of a genetic disease by genome editing of one allele achieved by the above-mentioned embodiment of the present invention. That is, a homozygous mutation or a heterozygous mutation (including a compound heterozygous mutation) that is believed to be the cause of a genetic disease can be repaired, alleviated, and / or prevented by genome editing of one allele achieved by the above-mentioned embodiment of the present invention. When a subject has a disease gene and a normal gene in a heterozygous state, the genetic disease can be treated, alleviated, and / or prevented by genome editing only the disease gene by the genome editing method of only one allele according to the embodiment of the present invention. When a subject has a disease gene in a homozygous state, the homozygous disease gene can be made heterozygous with the disease gene and the normal gene by genome editing of only one allele according to the embodiment of the present invention, thereby expressing a normal protein from the repaired allele, thereby treating, alleviating, and / or preventing the genetic disease. As described below, the genome editing of one allele achieved by the embodiment of the present invention can suppress off-target effects while maintaining on-target genome editing activity, and therefore has high therapeutic safety. The genetic disease that can be treated, alleviated and / or prevented by the genome editing of one allele according to the embodiment of the present invention is not particularly limited as long as it is a disease caused by a gene mutation, and examples thereof include, but are not limited to, cancer, sickle cell disease, Huntington's disease, Duchenne muscular dystrophy, fibrodysplasia ossificans progressiva (FOP), etc. The genome editing method of one allele of the embodiment above can be suitably performed to treat genetic diseases because cytotoxicity caused by genome editing is suppressed. In particular, in genome editing using a guide RNA in which one or more nucleotide residues are added to the 5' end of the spacer sequence for the target sequence in the disease gene (a1) described below, or an expression vector of the guide RNA, cytotoxicity caused by genome editing can be suppressed.

[0136] The present invention relates to, for example, (A) (a1) a guide RNA in which one or more nucleotide residues are added to the 5' end of a spacer sequence for a target sequence in a disease gene, (a2) a guide RNA including a spacer sequence having a mismatch of one or more bases with respect to the target sequence, and (a3) ​​at least one selected from the group consisting of an expression vector of the guide RNA of (a1) or (a2); (B) at least one selected from the group consisting of Cas proteins and their expression vectors; The present invention provides a method for treating, alleviating and / or preventing a genetic disease, comprising administering to a subject

[0137] The disease may be a disease caused by a heterozygous mutation (including a compound heterozygous mutation) or a disease caused by a homozygous mutation. The administration method of (A) and (B) is not particularly limited as long as it is a method that can cause genome editing of one allele, and may be oral administration or parenteral administration. Examples of parenteral administration include intravenous injection, intravenous drip, subcutaneous injection, intradermal injection, and intraperitoneal injection. (A) and (B) may be administered simultaneously or separately. The dosage of (A) and (B) varies depending on the degree of the disease, the subject's age, sex, weight, susceptibility difference, administration method, administration time, administration interval, administration period, the nature of the formulation, the type of active ingredient, etc., but can be appropriately set by a person skilled in the art.

[0138] The present invention relates to, for example, (A) (a1) a guide RNA in which one or more nucleotide residues are added to the 5' end of a spacer sequence for a target sequence in a disease gene, (a2) a guide RNA including a spacer sequence having a mismatch of one or more bases with respect to the target sequence, and (a3) ​​at least one selected from the group consisting of an expression vector of the guide RNA of (a1) or (a2); The present invention provides a pharmaceutical composition for treating, alleviating and / or preventing a genetic disease, comprising:

[0139] The pharmaceutical composition further comprises: (B) at least one selected from the group consisting of Cas proteins and their expression vectors; may include: Alternatively, the pharmaceutical composition comprises: (B) at least one selected from the group consisting of Cas proteins and their expression vectors; In this case, the other pharmaceutical composition may be administered simultaneously with the pharmaceutical composition of the present invention or separately.

[0140] The pharmaceutical composition of the present invention may be formulated by mixing with a pharma- ceutically acceptable carrier, etc. Examples of the pharma- ceutically acceptable carrier include excipients, binders, disintegrants, lubricants, colorants, flavorings, stabilizers, emulsifiers, absorption enhancers, surfactants, pH adjusters, preservatives, and antioxidants. The disease may be a disease caused by a heterozygous mutation (including a compound heterozygous mutation) or a disease caused by a homozygous mutation. The administration form of the pharmaceutical composition of the present invention is not particularly limited, and can be administered orally or parenterally. Examples of parenteral administration forms include intravenous injection, intravenous drip, subcutaneous injection, intradermal injection, and intraperitoneal injection. The dosage of the pharmaceutical composition of the present invention varies depending on the degree of the disease, the age, sex, weight, susceptibility difference of the subject, the administration method, the administration time, the administration interval, the administration period, the nature of the formulation, the type of active ingredient, and the like, but can be appropriately set by a person skilled in the art.

[0141] The present invention relates to, for example, For use in the treatment, mitigation and / or prevention of genetic disorders (A) (a1) a guide RNA in which one or more nucleotide residues are added to the 5' end of a spacer sequence for a target sequence in a disease gene, (a2) a guide RNA including a spacer sequence having a mismatch of one or more bases with respect to the target sequence, and (a3) ​​at least one selected from the group consisting of an expression vector for the guide RNA of (a1) or (a2), and (B) at least one selected from the group consisting of Cas proteins and their expression vectors; to provide. The disease may be a disease caused by a heterozygous mutation (including a compound heterozygous mutation) or a disease caused by a homozygous mutation.

[0142] The present invention relates to, for example, In the manufacture of a drug for the treatment, mitigation and / or prevention of a genetic disease, (A) (a1) a guide RNA in which one or more nucleotide residues are added to the 5' end of a spacer sequence for a target sequence in a disease gene, (a2) a guide RNA including a spacer sequence having a mismatch of one or more bases with respect to the target sequence, and (a3) ​​at least one selected from the group consisting of an expression vector for the guide RNA of (a1) or (a2), and (B) at least one selected from the group consisting of Cas proteins and their expression vectors; Provide for the use of. The disease may be a disease caused by a heterozygous mutation (including a compound heterozygous mutation) or a disease caused by a homozygous mutation.

[0143] In the above-mentioned [Treatment, alleviation and / or prevention of genetic disease by genome editing of one allele], instead of (A) and (B), cells derived from a subject in which a disease gene has been repaired by introducing (A) and (B) may be used. That is, by introducing the above-mentioned (A) and (B) into cells obtained from a subject, homozygous mutations or heterozygous mutations (including compound heterozygous mutations) that are believed to be the cause of a genetic disease in the cells are repaired by genome editing of one allele achieved by the above-mentioned embodiment of the present invention. By returning the cells in which the disease gene has been repaired (hereinafter referred to as "repaired cells") to the subject, normal proteins are expressed from the repaired cells, and the genetic disease can be treated, alleviated and / or prevented.

[0144] [Genetic disease model cells] In one embodiment, the present invention provides a method for producing a genetic disease model cell by genome editing of one allele achieved by the above embodiment of the present invention, and a model cell produced by the method. That is, for a gene known to be a causative gene of a genetic disease or a gene suspected to be a causative gene of a genetic disease, a normal gene of the gene is targeted, and an indel or a desired mutation is introduced into the one allele by genome editing of the one allele achieved by the above embodiment of the present invention, thereby producing a genetic disease model cell. The cell to be subjected to genome editing may have a normal gene in homozygous form, or may have a normal gene and a disease gene in heterozygous form. The genetic disease possessed by the genetic disease model cell of this embodiment is not particularly limited as long as it is a disease caused by a gene mutation, and examples thereof include, but are not limited to, cancer, sickle cell disease, Huntington's chorea, Duchenne muscular dystrophy, and fibrodysplasia ossificans progressiva (FOP).

[0145] The present invention relates to, for example, (A) (a1) a guide RNA in which one or more nucleotide residues are added to the 5' end of a spacer sequence for a target sequence in a normal gene of a causative gene of a genetic disease or a gene suspected of causing the genetic disease, (a2) a guide RNA including a spacer sequence having a mismatch of one or more bases with respect to the target sequence, and (a3) ​​at least one selected from the group consisting of an expression vector of the guide RNA of (a1) or (a2); (B) at least one selected from the group consisting of Cas proteins and their expression vectors; The present invention provides a method for producing a genetic disease model cell, which comprises a step of administering (introducing) the above into a cell in vitro.

[0146] The disease may be a disease caused by a heterozygous mutation (including a compound heterozygous mutation) or a disease caused by a homozygous mutation. The cells to which (A) and (B) are administered may be primary cultured cells or cell lines that have been immortalized. Examples of cell lines include human-derived Hela cells, African green monkey-derived COS7 cells, mouse-derived 3T3 cells, hamster-derived CHO cells, and rat-derived PC12 cells. The cells to which (A) and (B) are administered may be pluripotent stem cells, multipotent stem cells, unipotent stem cells, ES cells, or iPS cells. The cells to which (A) and (B) are administered may be, for example, human, mouse, rat, guinea pig, hamster, rabbit, dog, pig, cow, horse, sheep, monkey, or chicken cells. (A) and (B) may be administered simultaneously or separately. The method of administration (introduction method) of (A) and (B) to cells is not particularly limited, and known methods can be used. For example, the same method as described in the above section on [Method for producing cells in which only one allele has been genome-edited] <Introduction step> may be used.

[0147] [Non-human animal models of genetic diseases] In one embodiment, the present invention provides a method for producing a non-human model animal of a genetic disease by genome editing of one allele achieved by the above-mentioned embodiment of the present invention, and a non-human model animal produced by the method. That is, for a gene known to be a causative gene of a genetic disease or a gene suspected to be a causative gene of a genetic disease, a normal gene of the gene is targeted, and an indel or a desired mutation is introduced into one allele by genome editing of one allele achieved by the above-mentioned embodiment of the present invention, thereby producing a non-human model animal of a genetic disease. The animal to be subjected to genome editing may have a normal gene in a homozygous form, or may have a normal gene and a disease gene in a heterozygous form. The genetic disease of the genetic disease model animal of this embodiment is not particularly limited as long as it is a disease caused by a gene mutation, and examples thereof include, but are not limited to, cancer, sickle cell disease, Huntington's chorea, Duchenne muscular dystrophy, and fibrodysplasia ossificans progressiva (FOP).

[0148] The present invention relates to, for example, (A) (a1) a guide RNA in which one or more nucleotide residues are added to the 5' end of a spacer sequence for a target sequence in a normal gene of a causative gene of a genetic disease or a gene suspected of causing the genetic disease, (a2) a guide RNA including a spacer sequence having a mismatch of one or more bases with respect to the target sequence, and (a3) ​​at least one selected from the group consisting of an expression vector of the guide RNA of (a1) or (a2); (B) at least one selected from the group consisting of Cas proteins and their expression vectors; The present invention provides a method for producing a non-human animal model of a genetic disease, comprising the step of administering to the non-human animal a gene that is capable of expressing a genetic disease.

[0149] In one embodiment, the present invention may be a method for producing a non-human model animal for a genetic disease, comprising the step of administering the genetic disease model cell to a non-human animal. In one embodiment, the present invention may be a method for producing a non-human model animal for a genetic disease, comprising the step of injecting the (A) and (B) or the genetic disease model cell into a fertilized egg of a non-human animal.

[0150] The disease may be a disease caused by a heterozygous mutation (including a compound heterozygous mutation) or a disease caused by a homozygous mutation. As the non-human animal to which (A) and (B) are administered, any experimental animal available in the art, such as a mouse, rat, guinea pig, hamster, rabbit, dog, pig, cow, horse, sheep, monkey, chicken, etc., can be used. The method of administration of (A) and (B) is not particularly limited as long as it is a method that can cause genome editing of one allele, and may be administered orally or parenterally. Examples of parenteral administration include intravenous injection, intravenous drip, subcutaneous injection, intradermal injection, and intraperitoneal injection. (A) and (B) may be administered simultaneously or separately. The dosage of (A) and (B) varies depending on the type, week / month age, sex, weight, sensitivity difference, administration method, administration time, administration interval, administration period, etc. of the non-human animal to be administered, but can be appropriately set by a person skilled in the art. EXAMPLES

[0151] The present invention will be described below with reference to examples, but the present invention is not limited to the following examples.

[0152] The main abbreviations used in the following examples have the following meanings: P2A-tdTomato allele: An allele in which the P2A-tdTomato chimeric gene has been knocked in P2A-Venus allele: An allele in which the P2A-Venus chimeric gene is knocked in P2A-Neo allele: An allele in which the P2A-Neo chimeric gene is knocked in. All-in-one CRISPR plasmid: a plasmid expressing Cas9, sgRNA, and a selection marker p:RCP: All-in-one CRISPR plasmid with puromycin resistance gene (Puro) as a selection marker PX459:pSpCas9(BB)-2A-Puro(PX459)V2.0 plasmid(Addgene,plasmid #62988) P2A_PX459: PX459 with a spacer sequence targeted to the P2A peptide coding sequence inserted into the BpiI site aP2A_PX459: PX459 with a spacer sequence targeting the aP2A sequence inserted into the BpiI site PX459(del_Cas9-T2A-Puro): A plasmid in which the Cas9-T2A-Puro chimeric gene was deleted from PX459 Cdh1-P2A-tdTomato KI vector: A knock-in vector for knocking in the P2A-tdTomato chimeric gene downstream of the Cdh1 gene Cdh1-P2A-Venus KI vector: A knock-in vector for knocking in the P2A-Venus chimeric gene downstream of the Cdh1 gene Tbx3-P2A-tdTomato KI vector: A knock-in vector for knocking in the P2A-tdTomato chimeric gene downstream of the Tbx3 gene Tbx3-P2A-Venus KI vector: A template plasmid for knocking in the P2A-Venus chimeric gene downstream of the Tbx3 gene Cdh1-aP2A-tdTomato KI vector: A knock-in vector for knocking in the aP2A-tdTomato chimeric gene downstream of the Cdh1 gene Cdh1-aP2A-Venus KI vector: A knock-in vector for knocking in the aP2A-Venus chimeric gene downstream of the Cdh1 gene Tbx3-P2A-Neo KI vector: A knock-in vector for knocking in the P2A-Neo chimeric gene downstream of the Tbx3 gene Cdh1-P2A-AIMS: AIMS cells carrying the Cdh1-P2A-tdTomato chimeric gene and the Cdh1-P2A-Venus chimeric gene at both Cdh1 loci. Tbx3-P2A-AIMS: AIMS cells carrying the Tbx3-P2A-tdTomato chimeric gene and the Tbx3-P2A-Venus chimeric gene at both Tbx3 loci. Cdh1-aP2A-AIMS: AIMS cells carrying the Cdh1-aP2A-tdTomato chimeric gene and the Cdh1-aP2A-Venus chimeric gene at both Cdh1 loci. P2A(mismatch): A spacer sequence with a single base mismatch to the target sequence within the P2A peptide coding sequence aP2A(mismatch): a spacer sequence with one base mismatch to the target sequence within the aP2A sequence P2A(nX): a spacer sequence targeting the P2A peptide coding sequence with n nucleotide residues X added to the 5' end aP2A(nX): a spacer sequence that targets the aP2A sequence, with n nucleotide residues X added to the 5' end P2A(5'addition): A spacer sequence targeted to the P2A peptide coding sequence with any number of nucleotide residues added to the 5' end. aP2A(5'addition): A spacer sequence that targets the aP2A sequence with any number of nucleotide residues added to the 5' end P2A(mismatch_nX): a spacer sequence having one base mismatch with the target sequence in the P2A peptide coding sequence and having n nucleotide residues X added to the 5' end.

[0153] The plasmids, linkers, primers, etc. used in the following examples are shown in Tables 3 to 5. [Table 3]

[0154] [Table 4]

[0155] [Table 5]

[0156] [Example 1] Cultivation of mouse ES cells Mouse ES cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Nacalai Tesque) containing 2 mM Glutamax (Nacalai Tesque), 1x non-essential amino acids (NEAA) (Nacalai Tesque), 1 mM sodium pyruvate, 100 U / mL penicillin, 100 μg / mL streptomycin (P / S) (Nacalai Tesque), 0.1 mM 2-mercaptoethanol (Sigma), and 15% fetal bovine serum (FBS) (GIBCO), and further supplemented with 1 μM or 0.2 μM PD0325901 (Sigma), 3 μM CHIR99021 (Cayman), and 1,000 U / mL recombinant mouse LIF (Millipore). Cells were maintained under feeder-free conditions at 37°C and 5% CO2. When the cells were passaged, Y-27632 (10 μM, Sigma) was added.

[0157] [Example 2] Construction of AIMS (Overview of AIMS) Figure 1 is a diagram for explaining the outline of the AIMS constructed in this example. Figure 1A is a diagram for explaining the gene constitution of the AIMS cell prepared in this example, and Figure 1B is a diagram for explaining the method of evaluating indels by AIMS.

[0158] In the AIMS cells of this embodiment, Cdh1 (E-cadherin gene) or Tbx3 (TBX3 protein gene) is used as the localization protein coding sequence. The P2A peptide coding sequence is used as the cleavage site coding sequence. The tdTomato gene is used as the first fluorescent protein coding sequence, and the Venus gene is used as the second fluorescent protein coding sequence. Therefore, the first chimeric gene in the first allele has a structure of Cdh1-P2A-tdTomato or Tbx3-P2A-tdTomato, and the second chimeric gene in the second allele has a structure of Cdh1-P2A-Venus or Tbx3-P2A-Venus (Figure 1A).

[0159] In AIMS cells having the genetic structure of Figure 1A, the chimeric protein expressed from each chimeric gene is cleaved at the P2A peptide sequence and separated into a localized protein and a fluorescent protein. Therefore, the fluorescent protein is distributed throughout the cell without being localized (Figure 2B "wt"). Therefore, when wild type (wt) AIMS cells are observed under a fluorescent microscope, fluorescence is observed throughout the cell.

[0160] On the other hand, when genome editing is performed by the CRISPR / Cas system using sgRNA targeting the P2A coding sequence, the expression and localization of the fluorescent protein changes depending on the type of indel introduced into the P2A peptide coding sequence by the genome editing. That is, when a frameshift indel is introduced into the P2A coding sequence, the fluorescent protein is not expressed due to the frameshift (Figure 1B frame-shift).

[0161] Furthermore, when an in-frame indel is introduced into the P2A peptide coding sequence, it is no longer cleaved by the P2A peptide. Therefore, the chimeric protein expressed from the first or second chimeric gene is localized in the cell depending on the type of localization protein without being cleaved by the P2A peptide sequence. When the localization protein is Tbx3, the AIMS protein is localized to the nucleus (Figure 1B in-frame, Tbx3-AIMS). When the localization protein is Cdh1, the AIMS protein is localized to the cell membrane (Figure 1B in-frame, Cdh1-AIMS).

[0162] Therefore, when the fluorescence of both tdTomato and Venus disappears or localizes, it can be determined that indels have occurred in both the first allele (P2A-tdTomato allele) and the second allele (P2A-Venus allele). When the fluorescence of only one of tdTomato and Venus disappears or localizes, it can be determined that indels have occurred in only one of the P2A-tdTomato allele and the P2A-Venus allele. When the fluorescence of both tdTomato and Venus does not disappear or localize, it can be determined that indels have not occurred in either the P2A-tdTomato allele or the P2A-Venus allele. As described above, the bilateral indel introduction rate and the unilateral indel introduction rate can be evaluated by using AIMS cells.

[0163] FIG. 1C shows the P2A coding sequence used in the production of AIMS cells in this example. The region enclosed as "target" in the figure is the target sequence of the sgRNA. In the figure, the sequence shown as aP2A is a sequence in which a silent mutation has been introduced into the P2A coding sequence. In the production of AIMS cells described below, either the P2A coding sequence or the aP2A coding sequence was used.

[0164] (Construction of knock-in plasmid for producing AIMS cells) The 5' and 3' arms of Cdh1 were ligated to a plasmid containing the P2A-Venus chimeric gene or a plasmid containing the P2A-tdTomato chimeric gene to generate the Cdh1-P2A-tdTomato KI vector and the Cdh1-P2A-tdTomato KI vector. The 5' arm of Cdh1 was designed so that the end of the Cdh1 coding sequence was linked in frame to the P2A coding sequence to produce E-cadherin (Cdh1) and a fluorescent protein (tdTomato or Venus) independently, respectively. The Tbx3-P2A-tdTomato KI vector and the Tbx3-P2A-tdTomato KI vector were constructed in the same manner as above, except that the 5' arm and the 3' arm of Tbx3 were used instead of the 5' arm and the 3' arm of Cdh1. Cdh1-aP2A-tdTomato KI vector and Cdh1-aP2A-tdTomato KI vector were constructed in the same manner as above, except that the aP2A sequence was used instead of the P2A sequence.

[0165] (Construction of an all-in-one CRISPR plasmid) An adaptor linker for sgRNA (SEQ ID NO: 63, 64) containing a coding sequence of a spacer sequence targeting a target sequence in Tbx (3'-CCAGTTTGGTCAAATCTGCCAGT-5' (SEQ ID NO: 94)) was ligated to the BpiI site of PX459 to prepare an all-in-one CRISPR plasmid for AIMS cell production. Similarly, an adaptor linker for sgRNA (SEQ ID NO: 65, 66) containing a coding sequence of a spacer sequence targeting a sequence in Cdh was ligated to the BpiI site of PX459 to prepare an all-in-one CRISPR plasmid for AIMS cell production. The sgRNA targeting downstream of the stop codon was designed using CRISPR DESIGN (crispr.mit.edu / ).

[0166] (Preparation of AIMS cells) The all-in-one CRISPR plasmid, Cdh1-P2A-tdTomato KI vector, and Cdh1-P2A-Venus KI vector prepared above were simultaneously introduced into mouse ES cells using Lipofectamine® 3000 (ThermoFisher SCIENTIFIC). ES cells isolated with trypsin (Nacalai Tesque) were seeded into 500 μL of 2iL+Y medium dispensed into a gelatin-coated 24-well plate. A nucleic acid-Lipofectamine 3000 complex was prepared according to the standard protocol of Lipofectamine 3000. 1 μL of Lipofectamine 3000 was added to 25 μL of Opti-MEM medium (ThermoFisher SCIENTIFIC). In addition, 250 ng of the three plasmids and 1 μL of P3000 reagent were added to another 25 μL of Opti-MEM medium and mixed. These mixtures were mixed together and incubated at room temperature for 5 minutes. Then, they were added to the 24-well plate seeded with ES cells. After the cells naturally settled to the bottom of the plate, the plate was centrifuged at 600g and 37°C for 1 hour, and then incubated overnight. After 1-2 days of transfection, the cells were treated with puromycin (12 μg / mL) for 24-48 hours. Puromycin-resistant cells selected by puromycin treatment were cultured in the absence of puromycin for several days, and dual color-positive colonies were picked. The genotypes of the picked colonies were confirmed by PCR. Cells in which the introduction of the Cdh1-P2A-tdTomat chimeric gene and the Cdh1-P2A-Venus chimeric gene was confirmed in both alleles, respectively, were used as Cdh1-P2A-AIMS.

[0167] Tbx3-P2A-AIMS was prepared in the same manner as above, except that the Tbx3-P2A-Venus KI vector and the Tbx3-P2A-tdTomato KI vector were used instead of the Cdh1-P2A-Venus KI vector and the Cdh1-P2A-tdTomato KI vector.

[0168] Cdh1-aP2A-AIMS was prepared in the same manner as above, except that the Cdh1-P2A-Venus KI vector and the Cdh1-aP2A-tdTomato KI vector were used instead of the Cdh1-P2A-Venus KI vector and the Cdh1-P2A-tdTomato KI vector.

[0169] (Indel pattern analysis using AIMS cells) Analysis of indel patterns using AIMS cells was performed as follows. A target sequence was set within the P2A peptide coding sequence or the aP2A sequence to design an sgRNA. The coding sequence of the spacer sequence of the sgRNA was ligated to the BpiI site of PX459 to prepare a p:RCP. The structure of the p:RCP used in the examples is shown in FIG. 2A.

[0170] Using Lipofectamine® 3000 (ThermoFisher SCIENTIFIC), p:RCP was transfected into AIMS cells (Cdh1-P2A-AIMS, Tbx3-P2A-AIMS, or Cdh1-aP2A-AIMS). Transfection and puromycin treatment were performed in the same manner as described in the above section "(Preparation of AIMS cells)" except that AIMS cells were used as cells and p:RCP was used as a plasmid. Puromycin-resistant cells selected by puromycin treatment were cultured for several days in the absence of puromycin, and then subcultured and cloned. The cloned cells were observed for tdTomato and Venus fluorescence using a fluorescence microscope (inverted research microscope IX73, Olympus), and indels in both alleles were evaluated. Figure 2B shows the timeline from transfection to fluorescence analysis. In one transfection, 30–170 clones were analyzed for indel patterns. Transfection and subsequent indel pattern analysis were performed at least three times for each sgRNA.

[0171] [Example 3] Evaluation of the mismatch method We investigated whether the introduction rate of bilateral indels and unilateral indels changes by introducing a single-base mismatch with respect to the target sequence into the spacer sequence of sgRNA. A single-base mismatch spacer sequence was designed in which one base of the target sequence of P2A (TAACTTCAGCCTGCTGAAGC: SEQ ID NO: 95) was replaced with a different base (see FIG. 3A). An adapter sequence for ligation to the BpiI site of PX459 was added to the coding sequence of the spacer sequence having a single-base mismatch at the base (position 1) adjacent to the PAM to prepare an adapter linker for single-base mismatch sgRNA (SEQ ID NO: 69, 70). A similar adapter sequence was added to prepare adapter linkers for single-base mismatch sgRNA in which the mismatch base is at positions 2 to 20 (the base adjacent to the PAM is at position 1, and the base is at positions 2 to 20 in the 3'→5' direction). The sequences of the adapter linkers for sgRNAs that do not have mismatches in the P2A target sequence are shown in SEQ ID NOs: 67 and 68. Similarly, one base mismatch spacer sequence was designed in which any one of the target sequences of aP2A (TAGTCTACTAAAACAAGCCG: SEQ ID NO: 96) was replaced with a different base, and an adapter sequence was added to the coding sequence of the spacer sequence to prepare an adapter linker for one base mismatch sgRNA. The sequences of the adapter linker for one base mismatch sgRNA, which has one base mismatch at the base (position 1) adjacent to the PAM for the target sequence of aP2A, are shown in SEQ ID NOs: 73 and 74. The other adapter linkers for one base mismatch sgRNA are similar except that the position of the mismatch is different. The sequences of the adapter linker for sgRNA without a mismatch in the aP2A target sequence are shown in SEQ ID NOs: 71 and 72. These single-base mismatch sgRNA adaptor linkers were each inserted into the BpiI site of the PX459 plasmid to produce each P2A(mismatch)_PX459. Each of these P2A(mismatch)_PX459 was introduced into AIMS cells, and indels were evaluated.

[0172] The results are shown in Figure 3. Figure 3B shows the results of indel pattern analysis using Tbx3-P2A-AIMS as AIMS cells. The horizontal axis of the graph in Figure 3B shows the P2A target sequence, and below it, the bases after substitution in P2A (mismatch) are shown. The distance of the substituted base from the PAM (the position of each base when the base adjacent to the PAM is set to 1) is shown at the top of the graph. "P" is the case where P2A_PX459 (no mismatch) was used, and "N" is the case where PX459 (no spacer sequence) was used. As shown in Figure 3B, when P2A_PX459 was used, bilateral indels were introduced almost 100% of the time. On the other hand, when P2A(mismatch)_PX459 was used, the introduction rate of unilateral indels was higher. In addition, differences in the tendency to introduce indels were observed depending on the position where the mismatch was introduced.

[0173] Figure 3C shows the results of indel pattern analysis using Tbx3-P2A-AIMS as AIMS cells. The upper part of the graph in Figure 3C shows the position of the target sequence from the PAM, and the horizontal axis of the graph shows the base in the spacer sequence corresponding to that position. The underlined bases are the bases that match the target sequence. As shown in FIG. 3C, differences were observed in the indel introduction rate, bilateral allele indel introduction rate, and unilateral allele indel introduction rate depending on the position at which the mismatch was introduced and the type of mismatch base.

[0174] Figure 3D shows the results of indel pattern analysis using Cdh1-aP2A-AIMS as AIMS cells. The graph notation in Figure 3D is the same as in Figure 3B. As shown in Figure 3D, when a perfect match sgRNA was used, almost 100% of bilateral alleles of indel were introduced. On the other hand, when aP2A (mismatch)_PX459 was used, the rate of introduction of one-sided allele indel was high. In addition, differences in the tendency of indel introduction were observed depending on the position where the mismatch was introduced. There was a difference in the tendency of indel introduction from Figure 3B.

[0175] These results confirmed that the proportion of one-side allele indels can be adjusted by selecting the position at which a single mismatch is introduced and the type of mismatched base.

[0176] [Example 4] Evaluation of 5' nucleotide addition method (Indel introduction by P2A(5'addition)_PX459) We investigated whether the introduction rate of bilateral indels and unilateral indels changes by adding nucleotide residues to the 5' end of the spacer sequence of sgRNA. Spacer sequences were designed with 0 to 40 cytosines added to the 5' side of the P2A target sequence (see Figure 4A). Adapter sequences for ligation to the BpiI site of PX459 were added to the coding sequences of these spacer sequences to create adapter linkers for 5'C-added sgRNAs. Similarly, a spacer sequence was designed with 15 guanines, adenines, or uracils added to the 5' side of the target sequence of P2A, and an adapter sequence was added to the coding sequence of the spacer sequence to prepare adapter linkers for P2A(15G), P2A(15A), and P2A(15U) sgRNA, respectively. These adapter linkers for sgRNA were inserted into the BpiI site of the PX459 plasmid, respectively, to prepare P2A(5'addition)_PX459. As an example of the sgRNA adaptor linker used in the preparation of the above plasmid, the sequence of the sgRNA adaptor linker that adds 15G to the 5' end of the spacer sequence is shown in SEQ ID NOs: 75 and 76. Other sgRNA adaptor linkers also have the same sequence, except for the number and type of nucleotide residues added to the 5' end of the spacer sequence. The sequences of the sRNA adaptor linkers that add 5C to the 5' end of the spacer sequence targeting aP2A are shown in SEQ ID NOs: 81 and 82. The P2A(5'addition)_PX459 prepared above was introduced into AIMS cells, and indels were evaluated.

[0177] The results are shown in Figure 4B and Figure 4C. Figure 4B shows the results of indel pattern analysis using Cdh1-P2A-AIMS as AIMS cells. The horizontal axis of the graph in Figure 4B shows the nucleotide residues added to the 5' end of the target sequence. As shown in Figure 4B, when P2A_PX459(0C) was used, bilateral indels were introduced almost 100%. On the other hand, the indel introduction rate decreased as the number of added cytosines increased. In addition, the introduction rate of unilateral indels increased as the number of added cytosines increased. However, when the number of added cytosines was 25 or more, no difference in the tendency to introduce indels was observed.

[0178] Figure 4C shows the results of indel pattern analysis using Cdh1-P2A-AIMS as AIMS cells. The graph notation in Figure 4C is the same as in Figure 4B. As shown in Figure 4C, differences in the indel introduction rate and the introduction rate of one-sided allele indel were observed depending on the type of nucleotide added. When adenosine (A) was added, the indel introduction rate hardly decreased, and the introduction rate of one-sided allele indel was also low. The indel introduction rate decreased in the order of guanosine (G) and cytosine (C), and the introduction rate of one-sided allele indel increased. When uridine (U) was added, the indel introduction rate decreased significantly, and the introduction of both-sided allele indel was hardly observed.

[0179] Furthermore, we also confirmed whether the indel introduction rate would change by adding a nucleotide residue to the 3' end of the spacer sequence of sgRNA. Except for using the sequence of the sgRNA adaptor linker (SEQ ID NO: 77-80) that adds 5C or 10C to the 3' end of the spacer sequence, P2A(3'addition)_PX459 was prepared in the same manner as above, introduced into AIMS cells, and the indel introduction rate was evaluated. As a result, regardless of whether 5C or 10C was added to the 3' end, the indel introduction rate was almost 0%. This is thought to be because when a sequence is added to the 3' end of the spacer sequence, an extra sequence is interposed between the spacer sequence and the PAM sequence.

[0180] (Effect of the amount of sgRNA expression plasmid used on indel introduction rate) The decrease in the indel introduction rate by adding nucleotide residues to the 5' side of the target sequence may be due to the suppression of sgRNA transcription by the added nucleotide residues. Therefore, we evaluated the effect of the amount of sgRNA expression plasmid used for transfection on the indel introduction rate.

[0181] [Effect of the amount of p:RCP used during transfection] Tbx3-P2A-AIMS was used as mouse ES cells for AIMS, and was transfected with P2A_PX459. The amount of P2A_PX459 used for transfection was 2.5 ng, 25 ng, 250 ng, or 2500 ng.

[0182] The results are shown in Figure 4D. In Figure 4D, the left panel shows the results of indel analysis, and the right panel shows the number of colonies obtained after transfection with P2A_PX459. As shown in the right panel of Figure 4D, the number of colonies decreased when the amount of P2A_PX459 used was reduced. This was thought to be because the introduction rate of P2A_PX459 into AIMS cells decreased with the decrease in the amount of p:RCP used during transfection, resulting in a decrease in the number of cells that became puromycin resistant. On the other hand, in the cells that became puromycin resistant, bilateral indels were introduced in almost 100%.

[0183] [Effect of the amount of sgRNA expression plasmid used during transfection] In the above test, p:RCP was used, which expresses all of sgRNA, Cas9, and puromycin resistance genes, so it is possible that bilateral indels were introduced in almost 100% of the puromycin-resistant cells obtained after transfection. Therefore, PX459 (del_Cas9-T2A-Puro) was produced by cleaving PX459 with KpnI and NotI, blunting the cut ends with T4 polymerase, and ligating them. The coding sequence of the spacer sequence targeting aP2A was inserted into the BpiI site of PX459 (del_Cas9-T2A-Puro) to produce aP2A_PX459 (del_Cas9-T2A-Puro). A variety of amounts (0-250 ng) of aP2A_PX459 (del_Cas9-T2A-Puro) were cotransfected with a constant amount (250 ng) of PX459 (without spacer sequence) into AIMS cells. Cdh1-aP2A-AIMS was used for the AIMS cells.

[0184] The results are shown in Figure 4E. As the amount of aP2A_PX459 (del_Cas9-T2A-Puro) used decreased, the indel introduction rate decreased, but the introduction rate of one-sided allele indels hardly increased.

[0185] These results confirmed that reducing the amount of sgRNA expression plasmid used during transfection did not increase the rate of introduction of single-allelic indels.

[0186] (Genome editing of ROSA26 and albumin genes) The following adaptor linker sequences were inserted into the BpiI site of PX459 to prepare 10C (8A) linker PX459 and 25C (23A) linker PX459, respectively. By inserting the coding sequence of the desired spacer sequence into the BPiI site of these plasmids, sgRNAs with 10C and 23C added to the 5' side can be expressed. However, in these plasmids, the 8th C of 10C and the 23rd C of 25C are each replaced with A to introduce the overhang sequence CACC for ligation to the BPiI site. 10C(8A) Adapter Linker: (F) 5'-CACCGCCCCCCCACCGGGTCTTCGAGAAGACCT-3' (SEQ ID NO: 59) (R) 5'-AAACAGGTCTTCTCGAAGACCCGGTGGGGGGGC-3' (SEQ ID NO: 60) 25C(23A) Adapter Linker: (F) 5'-CACCGCCCCCCCCCCCCCCCCCCCCCCCCACCGGGTCTTCGAGAAGACCT-3' (SEQ ID NO: 61) (R) 5'-AAACAGGTCTTCTCGAAGACCCGGTGGGGGGGGGGGGGGGGGGGGGGGC-3' (SEQ ID NO: 62)

[0187] The coding sequence of the spacer sequence targeting Rosa26 or the coding sequence of the spacer sequence targeting the albumin gene (Alb) was inserted into the BPiI site of the 10C (8A) linker PX459 or 25C (23A) linker PX459 to prepare Rosa26_PX459 (10C (8A)), Rosa26_PX459 (25C (23A)), Alb_PX459 (10C (8A)), and Alb_PX459 (25C (23A)). The sequences of the linkers for preparing sgRNA targeting Rosa26 are shown in SEQ ID NOs: 87 and 88. The sequences of the linkers for preparing sgRNA targeting Alb are shown in SEQ ID NOs: 89 and 90.

[0188] The above-prepared Rosa26_PX459(10C(8A)), Rosa26_PX459(25C(23A)), Alb_PX459(10C(8A)), or Alb_PX459(25C(23A)) was introduced into wild-type ES cells. Transfection and puromycin treatment were performed in the same manner as described in "(Preparation of AIMS cells)" above. Puromycin-resistant cells selected by puromycin treatment were cultured for several days in the absence of puromycin, and then subcultured and cloned. Genomes were recovered from colonies of cloned cells, and the presence or absence of indels in each allele was determined by PCR and sequence analysis.

[0189] The results are shown in Figure 4F. Even when genomic regions such as Rosa26 and Alb were targeted, it was confirmed that the introduction rate of uni-allelic indels was increased by adding cytosine to the 5' end of the spacer sequence.

[0190] Except for using wild-type mouse ES cells as the transfection cells and the plasmid prepared above as the transfection plasmid, transfection and puromycin treatment were performed in the same manner as described in Example 2 "(Indel pattern analysis using AIMS cells)" to select puromycin-resistant cells. The obtained puromycin-resistant cells were cultured for several days in the absence of puromycin, and then passaged to obtain cloned colonies. Genomic DNA was extracted from the colonies, and DNA fragments containing the target sequence of sgRNA were amplified by PCR and sequence analysis was performed to determine the presence or absence of indel. The sequences of PCR primers for indel analysis when Rosa26 is targeted are shown in SEQ ID NOs: 55 and 56. The sequences of PCR primers for indel analysis when the albumin gene is targeted are shown in SEQ ID NOs: 57 and 58.

[0191] The results are shown in Figure 4F. The horizontal axis of the graph in Figure 4F indicates the nucleotide residues added to the 5' end of the target sequence. Similar to the results in Figure 4B, when no nucleotide addition was performed (0C), bilateral indels were introduced almost 100%. On the other hand, in both the Rosa26 and albumin genes (Alb), the indel introduction rate decreased as the number of added cytosines increased. In addition, the introduction rate of unilateral indels increased with the addition of cytosines. These results confirmed that, even when an endogenous gene was targeted, the rate of introduction of a uniallelic indel was increased by adding a nucleotide residue to the 5' end of the target sequence.

[0192] [Example 5] Homologous recombination test using AIMS cells (Summary of evaluation method) Next, the rate of introduction of indel-free homologous recombination was evaluated using AIMS cells. FIG. 5A is a diagram outlining the method used in this study. In this study, p:RCP targeting a sequence in the P2A coding sequence and the Tbx3-P2A-Neo KI vector are cotransfected into Tbx3-P2A-AIMS. In Tbx3-P2A-AIMS into which both plasmids have been introduced, sgRNA and Cas9 targeting P2A are first expressed from the all-in-one CRISPR plasmid, which cleave the P2A coding sequence. Next, the P2A-Neo chimeric gene is knocked in downstream of the Tbx3 gene by homologous recombination with the Tbx3-P2A-Neo KI vector (see the left diagram in FIG. 5A). After cotransfection, the cells are cultured in the presence of puromycin, and then in the presence of geneticin, allowing the selection of cells in which the P2A-Neo chimeric gene has been knocked in by genome editing.

[0193] In cells in which the P2A-Neo chimeric gene is knocked into the P2A-tdTomat allele and the P2A-Venus allele does not contain an indel, the tdTomato fluorescence disappears and the Venus fluorescence is detected throughout the cell (Figure 5A, right panel (a)). In cells in which the P2A-Neo chimeric gene is knocked into the P2A-Venus allele and the P2A-tdTomato allele does not contain an indel, the Venus fluorescence disappears and the tdTomato fluorescence is detected throughout the cell (Figure 5A, right panel (b)). In cells in which the P2A-Neo chimeric gene is knocked into the P2A-Venus allele or the P2A-tdTomato allele and the P2A-tdTomato allele or the P2A-Venus allele contains a frameshift indel, the fluorescence of both Venus and tdTomato disappears (Figure 5A, right panel (c), left). In cells in which the P2A-Neo chimeric gene was knocked into the P2A-tdTomato allele and the P2A-Venus allele contained an in-frame indel, tdTomato fluorescence disappeared and Venus fluorescence was localized to the nucleus (Figure 5A, right panel (c), center). In cells in which the P2A-Neo chimeric gene was knocked into the P2A-Venus allele and the P2A-tdTomato allele contained an in-frame indel, Venus fluorescence disappeared and tdTomato fluorescence was localized to the nucleus (Figure 5A, right panel (c), right). In this way, we could evaluate whether the non-knocked-in allele contained an indel. Because simultaneous knock-in of both alleles is very rare, all the cases in which both tdTomato and Venus fluorescence disappeared were considered to be cases in which the P2A-Neo chimeric gene was knocked-in to one allele and a frameshift indel was generated to the other allele.

[0194] (Test Method) The P2A-Neo chimeric gene was amplified by PCR using Rosa26 mT / mG plasmid (Addgene, plasmid #17787) as a template. The sequences of the primers used in PCR are shown in SEQ ID NOs: 30 and 32. The P2A-Neo chimeric gene was replaced with the P2A-tdTomato chimeric gene of the Tbx3-P2A-tdTomato KI vector to prepare the Tbx3-P2A-Neo KI vector. The p:RCP containing the coding sequence of the spacer sequence to be tested and the Tbx3-P2A-Neo KI vector were co-transfected into Tbx3-P2A-AIMS, and puromycin treatment was performed. The conditions for co-transfection and puromycin treatment were the same as those described in Example 2, "(Indel pattern analysis using AIMS cells)". Three days after cotransfection, puromycin was removed and a medium containing geneticin (400 μg / mL, GIBCO) was added to select geneticin-resistant cells. The resulting geneticin-resistant cells were cloned and 9 clones were genotyped. As a result, knock-in of the P2A-Neo chimeric gene was confirmed in all 9 clones. From these results, it was confirmed that most of the geneticin-resistant clones were knock-in clones of the P2A-Neo chimeric gene. Furthermore, since Tomato fluorescence was observed in all 9 clones, it was determined that they were unilateral knock-in clones of the P2A-Venus allele.

[0195] Co-transfection was performed as described above, and geneticin-resistant cells were selected by puromycin and geneticin treatment. These cells were observed for tdTomato and Venus fluorescence using a fluorescence microscope (inverted research microscope IX73, Olympus) to evaluate whether the non-knocked-in allele contained indels. Analysis of 40 to 230 clones was performed in one co-transfection. Transfection and subsequent indel analysis were performed at least three times for one type of sgRNA.

[0196] (Evaluation of the mismatch method) As in Example 3, one base mismatch spacer sequence was designed in which any one of the target sequences of P2A (SEQ ID NO: 95) was replaced with a different base, and an adapter sequence was added to the coding sequence of the spacer sequence to prepare an adapter linker for one base mismatch sgRNA. These adapter linkers for one base mismatch sgRNA were inserted into the BpiI site of the PX459 plasmid, respectively, to prepare each P2A(mismatch)_PX459. Each of these P2A(mismatch)_PX459 was used as p:RCP for cotransfection.

[0197] The results are shown in FIG. 5B. The horizontal axis of the graph in FIG. 5B shows the position of the substituted base in the target sequence of P2A (the position of each base when the base adjacent to PAM is set to 1). In the spacer sequence, A in the target sequence was replaced with T, T with A, C with G, and G with C. "P" is the case where P2A_PX459 (no mismatch) was used. In the figure, "HR+wt" means that one allele has homologous recombination (HR) and the other allele does not contain indel, and "HR+indel" means that one allele has homologous recombination (HR) and the other allele contains indel. "Unknown" means anything other than those. As shown in Figure 5B, when P2A_PX459 was used, the rate of homologous recombination with indel was almost 100%. On the other hand, when P2A(mismatch)_PX459 was used, the rate of homologous recombination without indel increased. In addition, the rate of homologous recombination without indel differed depending on the position of the mismatch. These results confirmed that the mismatch method is an effective method for inducing homologous recombination without indels.

[0198] (Evaluation of the 5' nucleotide addition method) Spacer sequences with 10 or 20 cytosines added to the 5' side of the P2A target sequence (SEQ ID NO: 95) were designed, and adapter sequences were added to the coding sequences of these spacer sequences to prepare 5'C-added sgRNA adapter linkers. These sgRNA adapter linkers were inserted into the BpiI site of the PX459 plasmid to prepare P2A(5'added)_PX459. Each of these P2A(5'added)_PX459 was used as p:RCP for cotransfection.

[0199] The results are shown in Figure 5C. The horizontal axis of the graph in Figure 5C indicates the nucleotide residues added to the 5' end of the target sequence. "0C" is the case where P2A_PX459 (no 5' addition) was used. In the figure, the meanings of "HR+wt", "HR+indel", and "unknown" are the same as in Figure 5B. As shown in Figure 5C, when P2A_PX459 was used, the rate of homologous recombination with indels was almost 100%. On the other hand, when P2A(5')_PX459 was used, the rate of homologous recombination without indels increased. Furthermore, the rate of homologous recombination without indels increased with an increase in the number of added cytosines. These results confirmed that the 5' nucleotide addition method is an effective method for inducing homologous recombination without indels.

[0200] [Example 6] Combination of the mismatch method and the 5' nucleotide addition method We tested whether the introduction rate of one-sided indel alleles would increase by combining the mismatch method evaluated in Example 3 with the 5' nucleotide addition method evaluated in Example 4. Tbx3-P2A-AIMS was used as the AIMS cell.

[0201] FIG. 6A shows the results of using sgRNA with one base mismatch against the target sequence of P2A (SEQ ID NO: 95). P2A (mismatch)_PX459 was introduced into Tbx3-P2A-AIMS, and indels were evaluated. The distance of the substituted base from the PAM (the position of each base when the base adjacent to the PAM is set to 1) is shown at the top of the graph. "P" is the case where P2A_PX459 (no mismatch) was used. In the spacer sequence, A of the target sequence was replaced with T, T with A, C with G, and G with C. As in FIG. 3B of Example 3, when P2A_PX459 was used, bilateral indels were introduced in almost 100% of cases. On the other hand, when P2A(mismatch)_PX459 was used, the introduction rate of unilateral indels was high.

[0202] FIG. 6B shows the results of using sgRNA containing a spacer sequence with one base mismatch to the target sequence of P2A (SEQ ID NO: 95) and 10 cytosines added to the 5' end. P2A(mismatch_10C)_PX459 was introduced into Tbx3-P2A-AIMS, and indels were evaluated. The method of drawing the graph and the method of substituting the bases are the same as in FIG. 6A. "P" is the case where P2A(10C(8A))_PX459 was used. In the above, "P2A(10C(8A))" indicates that the 8th cytosine of the 10 cytosines added to the 5' end of the target sequence of P2A is substituted with adenosine. In Figure 6B, there was an overall increase in the rate of introduction of uniallelic indels compared to the results in Figure 6A.

[0203] FIG. 6C shows the results of using sgRNA containing a spacer sequence with one base mismatch to the target sequence of P2A (SEQ ID NO: 95) and 25 cytosines added to the 5' end. P2A(mismatch_25C)_PX459 was introduced into Tbx3-P2A-AIMS, and indel evaluation was performed. The method of drawing the graph and the method of substituting the bases are the same as in FIG. 6A. "P" is the case where P2A(25C(23A))_PX459 was used. In the above, "P2A(25C(23A))" indicates that the 23rd cytosine of the 25 cytosines added to the 5' end of the target sequence of P2A is substituted with adenosine. In Figure 6C, the indel introduction rate was lower than in Figures 6A and 6B. In particular, the bilateral indel introduction rate was significantly lower. As a result, the number of mismatch positions where only unilateral indels were induced increased.

[0204] These results demonstrated that the rate of introduction of one-sided indels can be controlled by combining the mismatch method and the 5' nucleotide addition method.

[0205] [Example 7] Calculation of indel induction rate (Probability: P) and prediction of one-sided allele indel frequency If the rate of indel induction in the target region by CRISPR-Cas9 is P, the frequency of uniallelic indels, biallelic indels, and no indels can be expressed by the following formulas (m), (b), and (n), respectively. Frequency of one-sided indel (mono) = 2 × P × (1-P) (m) Frequency of bilateral indels (bi) = P 2 (b) Frequency of no indels (none) = (1-P) 2 (n)

[0206] Here, if mono+bi+none=1, P can be calculated by the following formula (1). P = (2 × bi + mono) / 2 (1)

[0207] Therefore, from the results of Figures 3B to 3D, 4B, and 6A to 6C, the P value for each sgRNA was calculated using the above formula (1). Using these P values, the frequency of one-sided allele indels in each sgRNA was calculated using the above formula (m). FIG. 7 shows the correlation between the frequency of uniallelic indels calculated by formula (m) and the frequency of uniallelic indels actually detected in FIGS. 3B to 3D, 4B, and 6A to 6C.

[0208] As shown in Figure 7, there is a high correlation (R 2 = 0.8943). This result indicates that the frequency of one-sided indels can be predicted by formula (m).

[0209] [Example 8] Prediction of indel patterns (Pre-Demo-Prediction) Pre-Demo-Prediction is a simple test method for calculating the P value using the above formula (1). Pre-Demo-Prediction was performed according to the protocol shown in Figure 8A. The coding sequence of the spacer sequence for any target sequence was ligated to the BpiI site of PX459 to prepare p:RCP. The p:RCP was transfected into cells in the same manner as described in Example 2 "(Indel pattern analysis using AIMS cells)", and puromycin treatment was performed to select puromycin-resistant cells. The DNA of the obtained puromycin-resistant cells was extracted, the region containing the target sequence was amplified by PCR, and the amplified fragment was inserted into T-Easy Vector (pGEM-T Easy Vector System; Promega) for cloning. Sequence analysis of 20 to 30 clones was performed, and the percentage of clones in which indels were confirmed was calculated. This value was defined as the indel induction rate (P). Furthermore, the calculated P value was used to predict the frequency of uni-allelic indels, bi-allelic indels, and no indels, respectively, according to the above formulas (m), (b), and (n).

[0210] (Evaluation of indel pattern predictions) The albumin gene (Alb) was selected as the target gene for genome editing, and Alb_PX459, Alb(10C(8A))_PX459, and Alb(25C(23A))_PX459 were prepared as p:RCPs using a linker for sgRNA (SEQ ID NO: 89, 90) containing the coding sequence of a spacer sequence targeting Alb. These were introduced into wild-type ES cells, respectively, and Pre-Demo-Prediction was performed as described above. The prediction results are shown in the left diagram of Figure 8B.

[0211] Similarly, transfection of Alb_PX459 and puromycin treatment were performed to obtain colonies of puromycin-resistant cells. DNA was extracted from each puromycin-resistant cell colony, and sequence analysis of the region containing the target sequence was performed to analyze the indel pattern in each clone. From the results, the frequency of uni-allelic indel, bi-allelic indel, and no indel were calculated. The results are shown in the right panel of Figure 8B.

[0212] As shown in Figure 8B, the predicted values ​​by Pre-Demo-Prediction were similar to the actual indel patterns, indicating that Pre-Demo-Prediction can predict indel patterns.

[0213] [Example 9] Suppression of off-target effects by 5' nucleotide addition method (test using sgRNA with one base mismatch) Genome editing of the target sequence by sgRNA with a one-base mismatch can be considered as off-target genome editing because the target sequence and the spacer sequence do not match. Therefore, we investigated whether the 5' nucleotide addition method can suppress off-target effects. 9A shows the results of calculating the indel induction rate (P) by the above formula (1) based on the data of FIGS. 6A to 6C. Genome editing of the target sequence by sgRNA having a single base mismatch at positions 1 to 20 can be considered as off-target genome editing. As shown in FIG. 9A, the off-target effect could be suppressed by adding cytosine to the 5' end. For example, when an sgRNA with a mismatch at position 1 is used, if cytosine is not added, the indel induction rate (P) is approximately 1. However, when 10 cytosines are added to the 5' end of the spacer sequence, the indel induction rate (P) is significantly reduced. On the other hand, when an sgRNA without a mismatch is used, the indel induction rate (P) does not decrease significantly even if 10 cytosines are added. This result indicates that the 5' nucleotide addition method can suppress off-target effects while maintaining on-target genome editing activity.

[0214] (Verification of off-target effects in off-target regions in the genome) Indels in the MFAP1 gene region (GAGTCtaAGCAGAAGAAGAA: sequence number 91; parts that differ from the target sequence in the EMX1 gene are indicated in lowercase letters), which is an off-target region relative to the target sequence in the EMX1 gene (GAGTCCGAGCAGAAGAAGAA: sequence number 5 to 24 of sequence number 83 (linker for producing sgRNA)), were verified in HEK293T cells. The coding sequence of the spacer sequence targeting the EMX1 gene was inserted into the 10C(8A) linker PX459 or 25C(23A) linker PX459 prepared in Example 4 above, to prepare EMX1_PX459(10C(8A)) and EMX1_PX459(25C(23A)), respectively. The linkers used to prepare the plasmids are shown in SEQ ID NOs: 83 and 84. These plasmids were introduced into HEK293T cells. Transfection and puromycin treatment were performed in the same manner as described in "(Preparation of AIMS cells)" above. Indels were confirmed by T7E1 assay and sequence analysis. DNA extracted from transfected and puromycin-treated HEK293T cells was amplified by PCR (EMX1 on-target region amplification primers: SEQ ID NOs: 85, 86; MFAR off-target region amplification primers: SEQ ID NOs: 92, 93), and for 0C, the amplified fragment was inserted into a T-easy Vector for cloning. The induction rate (P) of indels was then determined by assay with T7E1 enzyme (NEB) and sequence analysis. For (P) other than 0C, the amplified PCR products were directly assayed with T7E1, and the (P) value was calculated from the ratio of the amount of cleaved bands, as shown in Figure 9B. By adding cytosine to the 5' end of the spacer sequence, the indel induction rate was significantly reduced in the off-target region of the MFAP1 gene compared to the target sequence (on-target region) in the on-target EMX1 gene. This result indicates that adding nucleotides to the 5' end can reduce off-target effects.

[0215] In addition to the 10C(8A) linker PX459 or 25C(23A) linker PX459 prepared above, 5C(3A) linker PX459, 15C(13A) linker PX459, 20C(18A) linker PX459, and 30C(28A) linker PX459 were prepared and inserted with coding sequences of spacer strings targeting the EMX1 gene to prepare EMX1_PX459(5C(3A)), EMX1_PX459(10C(8A)), EMX1_PX459(15C(13A)), EMX1_PX459(20C(18A)), EMX1_PX459(25C(23A)), and EMX1_PX459(30C(28A)), respectively. The linkers used to prepare the plasmids are shown in SEQ ID NOs: 117 to 124. These plasmids were introduced into HEK293T cells. Transfection and puromycin treatment were performed in the same manner as described in "(Preparation of AIMS cells)" above. Indels were confirmed by T7E1 assay and sequence analysis. DNA extracted from transfected and puromycin-treated HEK293T cells was amplified by PCR (EMX1 on-target region amplification primers: SEQ ID NOs: 85, 86; MFAR off-target region amplification primers: SEQ ID NOs: 92, 93), and for 0C, the amplified fragment was inserted into a T-easy Vector for cloning. The induction rate (P) of indels was then determined by assay with T7E1 enzyme (NEB) and sequence analysis. For (P) other than 0C, the amplified PCR products were directly assayed with T7E1, and the (P) value was calculated from the ratio of the amount of cleaved bands, as shown in Figure 9C. By adding cytosine to the 5' end of the spacer sequence, the indel induction rate was significantly reduced in the off-target region of the MFAP1 gene compared to the target sequence (on-target region) in the on-target EMX1 gene. This result indicates that adding nucleotides to the 5' end can reduce off-target effects.

[0216] [Example 10] Repair test of genetic disease mutation in fibrodysplasia ossificans progressiva (FOP) (cell line) Human iPS cells (wt / R206H) were used that had an FOP genetic disease mutation (R206H: a mutation from arginine (CGC) to histidine (CAC) at position 206) in one allele of the ACVR1 gene.

[0217] (FOP genetic disease mutation repair method) An outline of the FOP genetic disease mutation repair method is shown in Figure 10A. As a selective target sequence for the mutant allele (R206H) of the ACVR1 gene, (GGCTC[A]CCAGATTACACTGT: SEQ ID NO: 112; [] indicates the mutant base) was selected, and DNA (SEQ ID NO: 100, 101) was prepared by adding an adapter sequence to the target sequence. This was inserted into the BPiI site of PX459, 5C(3A) linker PX459, 10C(8A) linker PX459, and 15C(13A) linker PX459 to prepare ACVR1(R206H)_PX459, ACVR1(R206H)_PX459(5C(3A)), ACVR1(R206H)_PX459(10C(8A)), and ACVR1(R206H)_PX459(15C(13A)), respectively. As a result, we obtained sgRNAs containing sequences with 0, 5 (1 of which is A), 10 (1 of which is A), or 15 (1 of which is A) cytosines added to the 5' end of the spacer sequence, and plasmids expressing Cas9 for editing the mutant allele (R206H). When these plasmids were introduced into human iPS cells (wt / R206H), the mutant allele (R206H) was preferentially cleaved by Cas9 (Figure 10A, dotted arrow).

[0218] Next, a single-stranded oligo donor DNA (ssODN) having the base sequence shown in SEQ ID NO: 102 was prepared as a template DNA for repairing the mutant allele. The ssODN has a silent mutation [G] two bases 5' upstream of the [G] in addition to [G] that repairs the R206H mutation. The silent mutation [G] prevents further indel introduction after genome repair (Fig. 10A, black arrow). In addition, the presence of the ACVR1 gene (wt / correct) having a wt allele and a repaired allele (correct) can be confirmed. When genome editing of the mutant allele (R206H) is performed, deletion or long deletion of the mutant allele (R206H) often occurs due to the action of Cas9 (unknown indel). At this time, if the silent mutation [G] does not exist, a clone having a wt / unknown indel may be mistaken for a clone having a wt / correct. Furthermore, the silent mutation [G] introduces a restriction enzyme BstUI cleavage site, facilitating genotyping of the repaired clones.

[0219] Each of the plasmids and the ssODN was introduced into human iPS cells (wt / R206H) to induce HDR (homology directed repair).

[0220] (genotype analysis) Genotype analysis was performed on iPS cell clones in which HDR was induced by the above method, and the efficiency of HDR induction was confirmed. For clones after HDR induction, DNA at the target site was amplified by PCR using primers Pr.KW1181 (SEQ ID NO: 103) and Pr.KW1182 (SEQ ID NO: 104). For the amplified fragments cleaved with BustUI, sequence analysis was performed using Pr.KW1181.

[0221] (result) The results are shown in Figure 10B. In Figure 10B, "overall" is the percentage of clones containing genotypes other than wt / correct (indel / correct, wt / correct+indel, etc.) among clones in which HDR was induced. As shown in Figure 10B, with sgRNA (0C) with no cytosine added to the 5' end, correctly repaired wt / correct clones could not be obtained. On the other hand, with sgRNA (5C, 10C) with 5 or 10 cytosines added, wt / correct clones could be obtained.

[0222] (Evaluation of target genome cleavage efficiency) Either of the plasmids for editing the mutant allele (R206H) was introduced into human iPS cells (wt / R206H), and genome editing was performed targeting the mutant allele (R206H) in the ACVR1 gene sequence. The genome was then recovered from the cells, and DNA was PCR amplified using primers Pr.KW1181 and Pr.KW1182. The amplified fragment was then used to perform a cleavage assay with T7 Endonuclease I (T7E1) (purchased from NEB) to measure the indel induction efficiency.

[0223] The results are shown in Figure 10C. Compared to sgRNA without cytosine at the 5' end (0C), sgRNA with cytosine (5C, 10C, 15C) showed a significantly reduced indel induction efficiency. This reduction in indel induction efficiency was shown to be necessary for obtaining wt / correct clones (Figure 10B).

[0224] [Example 11] Preparation of FOP genetic disease model (cell line) Mouse ES cells (wt / wt) that do not have a mutation in the Acvr1 gene were used.

[0225] (Method of inducing FOP genetic disease mutation) An outline of the FOP genetic disease mutation induction method is shown in Figure 11A. As a target sequence for the Acvr1 gene (wt / wt), (GGCTCGCCAGATAACCCTGT: SEQ ID NO: 115) was selected, and DNA (SEQ ID NO: 105, 106) was prepared by adding an adapter sequence to the target sequence. This was inserted into the BPiI site of PX459, 5C(3A) linker PX459, 10C(8A) linker PX459, 15C(13A) linker PX459, 20C(18A) linker PX459, 25C(23A) linker PX459, and 30C(28A) linker PX459, to generate ACVR1(R206H)_PX459, ... 9(5C(3A)), ACVR1(R206H)_PX459(10C(8A)), ACVR1(R206H)_PX459(15C(13A)), ACVR1(R206H)_PX459(20C(18A)), ACVR1(R206H)_PX459(25C(23A)), and ACVR1(R206H)_PX459(30C(28A)) were generated, respectively. As a result, we obtained sgRNAs containing sequences with 0, 5 (1 of which is A), 10 (1 of which is A), 15 (1 of which is A), 20 (1 of which is A), 25 (1 of which is A), or 30 (1 of which is A) cytosines added to the 5' end of the spacer sequence, and Acvr1 gene (wt / wt) editing plasmids expressing Cas9. When these plasmids are introduced into mouse ES cells, the wt allele of the Acvr1 gene is cleaved by Cas9 (Figure 11A dotted arrow).

[0226] Next, an ssODN having the base sequence shown in SEQ ID NO: 107 was prepared as a template DNA for mutagenesis. The ssODN has [A] that induces the mutation of R206H.

[0227] The plasmids and the ssODN were introduced into mouse ES cells (wt / wt) to induce HDR (Homology Directed Repair). The plasmids can also induce indels in the mutant allele (R206H) of the heterozygous mutant clone (wt / R206H) (FIG. 11A white arrow), but the off-target suppression effect of the 5' nucleotide-added sgRNA suppresses the induction of indels in the mutant allele (R206H). Therefore, it was thought that it would be possible to efficiently obtain a heterozygous mutant clone (wt / R206H).

[0228] (genotype analysis) Genotype analysis was performed on the ES cell clones in which HDR was induced by the above method, and the efficiency of HDR induction was confirmed. For the clones after HDR induction, DNA of the target site was amplified by PCR using primers Pr.KW1201 (SEQ ID NO: 108) and Pr.KW1202 (SEQ ID NO: 109). Sequence analysis was performed on the amplified fragments using Pr.KW1201.

[0229] (result) The results are shown in Figure 11B. In Figure 11B, "overall" is the percentage of clones containing genotypes other than wt / R206H (indel / R206H, wt / R206H+indel, etc.) among clones in which HDR was induced. As shown in Figure 11B, the HDR induction efficiency was highest in sgRNA (5C) with five cytosines added to the 5' end. The HDR induction efficiency also decreased with the decrease in Cas9 activity due to the increase in the number of added cytosines (Figure 11C). On the other hand, the acquisition rate of heterozygous mutant clones (wt / R206H) increased with the decrease in Cas9 activity due to the increase in the number of added cytosines (Figure 11C).

[0230] (Evaluation of target genome cleavage efficiency) Either of the plasmids for editing the wt allele was introduced into mouse ES cells (wt / wt), and genome editing was performed by targeting the Acvr1 gene sequence. The genome was then recovered from the cells, and DNA was PCR amplified using primers Pr.KW1201 and Pr.KW1202. The amplified fragment was then used to perform a cleavage assay with T7 Endonuclease I (T7E1) (purchased from NEB) to measure the indel induction efficiency.

[0231] The results are shown in Figure 11C. It was confirmed that the indel induction efficiency decreased with an increase in the number of cytosines added. In Figure 11C, pX459 is a negative control using sgRNA without a spacer sequence.

[0232] (Creating an animal model of FOP genetic disease) The heterozygous mutant clone (wt / R206H) obtained in the above test was microinjected into mouse fertilized eggs to generate chimeric mice. In the chimeric mice, abnormal bone formation was observed at the site where the ES cells had contributed (arrow in Figure 11D). These results demonstrated that it is possible to generate an FOP genetic disease model animal.

[0233] [Example 12] Cytotoxicity evaluation test (Cytotoxicity evaluation test using AIMS) Genome editing of AIMS cells was performed using the P2A target sequence (TAACTTCAGCCTGCTGAAGC: SEQ ID NO: 95) as a target in the same manner as in Example 4. As a spacer sequence, a sequence in which 0 to 20 cytosines were added to the 5' end of the P2A target sequence was used. After genome editing, the number of cells was counted.

[0234] The results are shown in Figure 12A. In sgRNA (0C) without cytosine, the number of cells was reduced to 1 / 5 compared to sgRNA (5C) with five cytosines added. As shown in Figure 4B above, the indel induction efficiency in both sgRNA (0C) and sgRNA (5C) was almost 100%. Therefore, it was suggested that the addition of cytosine can suppress cytotoxicity that is not involved in genome cleavage and indel induction efficiency.

[0235] (Evaluation of cytotoxicity by genome editing targeting ACVR1) As a target sequence for the ACVR1 gene, (GGCTCGCCAGATTACACTGT: SEQ ID NO: 113) was selected, and DNA (SEQ ID NOs: 110 and 111) was prepared by adding an adapter sequence to the target sequence. This was inserted into the BpiI site of PX459, 5C(3A) linker PX459, 10C(8A) linker PX459, 15C(13A) linker PX459, and 20C(18A) linker PX459 to generate ACVR1(R206H)_PX459, ACVR1(R206H)_PX459(5C(3A)), ACVR1(R206H)_PX459(10C(8A)), ACVR1(R206H)_PX459(15C(13A)), and ACVR1(R206H)_PX459(20C(18A)), respectively. As a result, we obtained sgRNAs containing sequences with 0, 5 (1 of which is A), 10 (1 of which is A), 15 (1 of which is A) or 20 (1 of which is A) cytosines added to the 5' end of the spacer sequence, and wt / wt editing plasmids expressing Cas9. These plasmids were introduced into human iPS cells (wt / wt) to perform genome editing. After genome editing, the number of cells was counted.

[0236] The results are shown in Figure 12B. The number of cells was reduced to 1 / 22 in the case of sgRNA (0C) with no cytosine added, compared to the case of sgRNA (5C) with five cytosines added.

[0237] [Example 13] Calculation of indel induction rate (Probability: P) and prediction of indel frequency 253 data (consisting of all of C-added gRNA, mismatch gRNA, and C-added + mismatch gRNA) were obtained from AIMS, and based on these data, the P value was calculated using the above formula (1). The calculated P value was plotted on the horizontal axis, and the indel data value P for each of Bi, Meno, and None was plotted on the vertical axis. From this graph, a quadratic function formula was obtained (Figure 13A). By applying the P value to these obtained formulas, the indel ratios of Bi, Mono, and None can be predicted.

[0238] Figure 13B shows the relationship between the actual measured values ​​and the predicted values ​​by the above formula. The actual measured values ​​Bi indel (P), Mono indel (P), and None (P) are plotted on the horizontal axis and the predicted values ​​(Prediction) on the vertical axis. The actual measured values ​​and the predicted values ​​showed a high correlation. The lower diagram in Figure 13B is Bi indel(P) + Mono indel(P) + None(P) = 1, so it was generated as None(P) = 1 - Bi indel(P) - Mono indel(P).

[0239] The upper panel of Figure 13C shows actual data from genome editing targeting P2A using Cdh1-P2A-AIMS. The center diagram of FIG. 13C shows a prediction graph created from the obtained data by applying the P value calculated by the above formula (1) to the formula (P=x) of FIG. 13A. The lower diagram of Figure 13C shows an indel pattern prediction graph obtained by performing PCR on the genome extracted during the experiment in the upper diagram of Figure 13C, obtaining a P value from a bacterial (Escherichia coli) assay (Example 8: Pre-Demo-Prediction) performed according to the above-mentioned "Method for predicting genome editing patterns", and applying it to the formula in Figure 13A. Since the lower diagram of Figure 13C almost coincides with the upper diagram of Figure 13C, the accuracy of the formula in Figure 13A as well as the effectiveness of the bacterial assay were proven. Therefore, even if AIMS is not used and an endogenous gene (genome) is targeted, the allele-specific intel pattern can be accurately predicted by performing PCR on the cell genome after genome editing induction and performing a bacterial assay.

[0240] [Example 14] Prediction using Compound heterozygous Two target sequences, P2A-sgRNA1 (linker sequence numbers 67 and 68) and Cdh1-sgRNA4 (linker sequence numbers 125 and 126), were designed for Cdh1-P2A-AIMS ES cells (Figure 14A). Each unilateral indel was generated in a different allele (trans relationship), and a compound heterozygous indel clone was created in a single recombination operation (Figure 14B). The genotype was determined by the fluorescence pattern (for the P2A site: no sequencing required) and by sequencing the PCR product by PCR with the designed primers (endogenous Cdh1 gene region). The genotype of the Cdh1-sgRNA4 target region of the Tomato allele is Pr.KW1287 (sequence number 127) and Pr.KW1118 (sequence number 54). The genotypes of the Cdh1-sgRNA4 target region of the Venus allele are Pr.KW558 (sequence number 39) and Pr.KW1118 (sequence number 54).

[0241] The results are shown in Table 6.

[0242] [Table 6]

[0243] P2A-sgRNA1 and Cdh1-sgRNA4 were tested using a combination of sgRNA with 0 cytosines (0C) and sgRNA with 25 cytosines (25C). Compound heterozygous indel clones could not be obtained when [0C] was used together or when only Cdh1 was used [25C]. 21 clones were obtained when [25C] was used together. Therefore, it was shown that the induction of mono indels by reduced activity is essential for both targets.

[0244] From the occurrence probability of one-sided allele indels in 21 / 363 clones, the compound heterozygous indel probability was calculated as P = 0.050. We verified whether this P value could be predicted from the Mono P value by bacterial assay according to Figure 13. Using the [0C] sgRNA and [25C] sgRNA of P2A-sgRNA1 and Cdh1-sgRNA4, the predicted Mono P value was calculated from the formula in Figure 13A from the bacterial assay (Mono(P) in Table 6). The compound predicted P value was calculated as P2A Mono(P) x Cdh1 Mono(P) x 1 / 2 (probability of being in trans), and was 0.047. This predicted P value of 0.047 was almost consistent with the actual P value of 0.050, proving that the occurrence rate of compound heterozygous indels can also be accurately predicted by bacterial assay.

[0245] In this study, compound heterozygotes were created within a single gene, but a similar principle can also be applied to predict the probability of indel induction in multiple different genes, for example, when all genes are heterozygous, all are homozygous, or mixed.

[0246] For example, for three genes, Genes A to C, the predictions can be made as follows: All hetero type P=Gene A Mono(P) x Gene B Mono(P) x Gene C Mono(P) All homo type P=Gene A Bi(P) x Gene B Bi(P) x Gene C Bi(P) Mixed type P=Gene A Bi(P) x Gene B Mono(P) x Gene C None(P)

[0247] [Example 15] In vitro cleavage assay PCR was performed using the P.KW13-3 plasmid (SEQ ID NO: 4) as a template and Pr.KW541 (SEQ ID NO: 41) and Pr.KW607 (SEQ ID NO: 128) as primers. The sgRNA and Cas9 complex was allowed to act in vitro on 300 ng (951 bp) of PCR product, and the DNA cleavage activity of C-added gRNA-Cas9 was measured (cleaved DNA: 741 bp and 210 bp). [0C]sgRNA, [10C]sgRNA, and [25C]sgRNA were prepared by the following procedure. Using the PX459 plasmid into which the P2A-gRNA1 linker (SEQ ID NO: 67, 68) was inserted as a template, PCR was performed using forward primers (Pr.KW1105 (SEQ ID NO: 129), Pr.KW1106 (SEQ ID NO: 130), Pr.KW1107 (SEQ ID NO: 131)) and reverse primer (Pr.KW1108 (SEQ ID NO: 132)). The PCR products were subjected to in vitro transcription using T7 RNA polymerase to obtain each of the above sgRNAs. Cas9 protein was purchased from IDT.

[0248] The results are shown in Figure 15. It was confirmed that the DNA cleavage activity decreased in a C-chain length-dependent manner under the action of the same molar concentration of gRNA (200 nM). Therefore, it was shown that the 5' nucleotide addition method is effective not only in vivo (cell level) but also in vitro (in a test tube). [Industrial Applicability]

[0249] According to the present invention, there are provided a method for producing a cell in which only one allele has been genome-edited, a guide RNA, an expression vector, and a kit that can be used in the method. Further, there are provided a method for predicting genome editing patterns, a method for analyzing genome editing patterns, and cells that can be used in the analysis method.

Claims

1. (A) (a1) a guide RNA having one or more nucleotide residues added to the 5' end of a spacer sequence, (a2) a guide RNA including a spacer sequence having one or more mismatches with a target sequence, and (a3) ​​at least one selected from the group consisting of an expression vector for the guide RNA of (a1) or (a2); (B) at least one selected from the group consisting of Cas proteins and their expression vectors; A method for producing a cell in which only one allele has been genome edited, comprising the step of introducing the above gene into a cell.

2. The method for producing a cell in which only one allele has been genome-edited as described in claim 1, wherein (A) is a guide RNA or an expression vector encoding the same, in which one or more nucleotide residues are added to the 5' end of a spacer sequence, and the spacer sequence has a mismatch of one or more bases with respect to a target sequence.

3. The method for producing a cell in which only one allele has been genome-edited, as described in claim 1 or 2, wherein all of the nucleotide residues added to the 5' end of the spacer sequence are identical nucleotide residues.

4. The method for producing a cell in which only one allele has been genome-edited, as described in claim 3, wherein the nucleotide residue added to the 5' end of the spacer sequence is a cytosine residue or a guanine residue.

5. The method for producing a cell in which only one allele has been genome-edited according to any one of claims 1 to 4, further comprising the step of (C) introducing a donor vector into the cell.

6. The method for producing a cell in which only one allele has been genome-edited according to any one of claims 1 to 5, wherein the Cas protein is a Cas9 protein.

7. A guide RNA having one or more nucleotide residues added to the 5' end of a spacer sequence.

8. The guide RNA of claim 7, wherein the spacer sequence has one or more base mismatches with the target sequence.

9. An expression vector for a guide RNA according to claim 7 or 8.

10. The expression vector of claim 9 , further capable of expressing a Cas protein.

11. 11. The expression vector of claim 10, wherein the Cas protein is a Cas9 protein.

12. (A) A kit for producing a cell in which only one allele has been genome-edited, comprising at least one selected from the group consisting of: (a1) a guide RNA having one or more nucleotide residues added to the 5' end of a spacer sequence; (a2) a guide RNA including a spacer sequence having a mismatch of one or more bases with respect to a target sequence; and (a3) ​​an expression vector for the guide RNA of (a1) or (a2).

13. The manufacturing kit according to claim 12, further comprising (B) at least one selected from the group consisting of Cas proteins and their expression vectors.

14. (i) introducing a guide RNA or its expression vector, and a Cas protein or its expression vector into a cell to perform genome editing; (ii) extracting DNA from the genome-edited cells; (iii) amplifying a DNA fragment containing a target region from the DNA; (iv) performing sequence analysis of the amplified DNA fragment to determine the indel induction rate (P) in the target region; and (v) calculating the indel induction rate for only one allele (mono) and the indel induction rate for both alleles (bi) according to the following formula (m) or (m1) and (b) or (b1); A method for predicting genome editing patterns, comprising: mo=2×P×(1-P) ・・・(m) bi=P 2 ・・・(b) mono=-1.303P 2 +1.2761P+0.0274 ・・・(m1) <h2 style=";text-align:left;direction:ltr">bi=0.6515P<h2 style=";text-align:left;direction:ltr"> 2 <h2 style=";text-align:left;direction:ltr"> +0.3619P-0.0137 ・・・(b1)

15. one allele comprises a chimeric gene in which a localization protein coding sequence, a cleavage site, and a first fluorescent protein coding sequence are linked in frame in this order; The other allele contains a chimeric gene in which the localization protein coding sequence, the cleavage site, and a second fluorescent protein coding sequence are linked in frame in this order. cell.

16. (I) A step of introducing a guide RNA or an expression vector thereof targeting the cleavage site, and a Cas protein or an expression vector thereof into the cell according to claim 15 to perform genome editing; (II) after step (I), analyzing the fluorescence pattern of the cells; and (III) determining a genome editing pattern based on the fluorescence pattern analyzed in the step (II); A method for analyzing genome editing patterns, comprising:

Citation Information

Patent Citations

  • Crispr-CAS systems and methods for altering expression of gene products

    WO2014093661A2